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Executive summary  
Scope 
This survey was carried out to map existing national surveillance systems and prevention programmes for hepatitis 
B and C in the EU/EEA.  
Hepatitis B  
Surveillance in Europe 
All countries indicated that they maintain a passive mandatory reporting system for hepatitis B. In 15 countries 
there was only one specific surveillance system, whereas four countries had multiple surveillance systems. The 
national objectives of surveillance are very similar in different countries but the case definitions were not always in 
line with the objectives; eight countries indicated that they implemented the EU-2008 case definition, and three 
were using the EU-2002 case definition. In total, 21 countries were using a case definition that closely resembled 
the EU definition. Based on the various case definitions, 28 countries report confirmed cases, and 27 include acute 
hepatitis B cases. Chronic cases are included in the reports of 17 countries; asymptomatic cases are often omitted. 
Twenty-six countries reported to collect case-based data at the national level, but the frequency of analysis varies 
between countries. A basic data set (age, gender, place of residence, date of onset of disease, date of reporting) is 
collected in 26 countries, but detailed data on epidemiological risk and impact of the disease are often missing.  
Epidemiology in Europe 
The number of newly reported cases per 100 000 population in 2007 as reported by 27 countries ranges from 0 to 
15.0, with an average of 1.5 (Annual Epidemiological Report on Communicable Diseases in Europe 2009. 
Stockholm: ECDC; 2009). The number of reported HBV cases in the EU/EEA countries per 100 000 population has 
declined from 6.7 to 1.5 between 1995 and 2007. Tracking trends and making comparison between countries can 
be challenging, as surveillance systems differ considerably and recent changes may impact the presented data.  
Prevalence of HBV in the general population varies widely between countries, with low to intermediate HBsAg 
carrier rates in Slovakia (1.6%), Italy (1%), Belgium and France (around 0.6 %), Finland, Hungary, the United 
Kingdom (all below 0.5%), and Bulgaria (3.8%). Screening for HBV in pregnant women is conducted in 24 
countries, but not in Belgium, Bulgaria, Lithuania, Luxembourg and Romania. Prevalence in pregnant women varies 
between 1.15% in Greece and 0.14% in Finland. There are also screening programmes for injecting drug users (15 
out of 29 countries), prisoners (11 countries), STI clinic attendees (nine countries), and persons with multiple sex 
partners (two countries). HBV prevalence in IDU reported by eight countries was higher than in the general 
population. The prevalence in IDU varies widely, ranging between 0.5% in Norway and 50% in Denmark. 
Prevalence among healthcare workers in Denmark and Germany was shown to be similar to the general population.  
Screening and vaccination 
Universal vaccination programmes for infants, children or adolescents were implemented in 22 countries. Seven 
countries (Denmark, Finland, Iceland, Norway, Sweden, the Netherlands, and the United Kingdom) have 
implemented selective vaccination programmes targeted at risk groups. Additional prevention programmes for 
different risk groups were usually targeted at those at increased risk for HBV due to occupational exposure. In 
addition, there is a wide variety of risk-group vaccination programmes. Only half of the countries with a routine 
vaccination programme indicated heterogeneous coverage rates, but the coverage rate in infants (one to two years) 
seems to be above 95% (except in Austria, Malta, and France). 
Hepatitis C 
Surveillance in Europe 
All EU/EEA countries indicated that they have implemented a reporting system for hepatitis C (either national or 
targeted at one specific population). In 14 countries there was one specific surveillance system, but 15 countries 
indicated that they use multiple surveillance systems to monitor hepatitis C. The national objectives of surveillance 
are very similar in the different countries but it appears that case definitions were not always in line with the 
objectives. Eleven countries indicated that they have implemented the EU-2008 case definition, and four countries 
apply the EU-2002 case definition. Despite this, there is a wide variety in the implementation of case definitions in 
the Member States, especially in the case classification. All countries included confirmed acute cases in their 
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surveillance systems1
Epidemiology in Europe 
, and 18 countries also included chronic cases. Some countries indicated that they collected a 
mixture of cases, and no serological markers were available to differentiate between acute and chronic hepatitis C. 
This hampers the interpretation of available data across countries. Twenty-six countries reported to collect case-
based data at the national level, but the frequency of analysis varies between countries. In addition to clinical 
reporting, 19 countries collect data from laboratories as a part of their surveillance system; 10 countries do not 
include laboratory reporting. A basic data set (age, gender, place of residence, date of onset of disease, date of 
reporting) is collected in 26 countries, but information on detailed epidemiological risk and impact of the disease 
are often missing. Underreporting seems to be common, due to the asymptomatic character of the disease.  
The number of newly reported cases per 100 000 population in 2007, as reported by 27 Member States, range 
between 0 and 36, with an average incidence of 6.9 cases per 100 000 (AER, ECDC 2009). The number of reported 
HCV cases in the EU/EEA countries per 100 000 population has increased from 4.5 to 6.9 between 1995 and 2007. 
Plotting trends and comparing data between countries is difficult and needs to be done with caution, as 
surveillance systems differ considerably and recent changes may impact the presented data. For HCV, the 
interpretation is further hampered by the asymptomatic nature of infection so that reported numbers may reflect 
testing practices rather than true incidence and because no distinction can be made between acute and chronic 
disease.  
Prevalence data on HCV for the general population are rather scarce; prevalence ranges from 2.6% in Italy in 2007 
to 0.12% in Belgium in 2003. A relative high prevalence was reported by Bulgaria (1.2%) and Slovakia (1.56%). 
Eleven Member States reported prevalence data in IDU ranging from 25% to 75%. In 2006–07, Italy reported the 
lowest prevalence (10.8%–25.6%) and Norway the highest (70%). The HCV prevalence data are based on 
serological markers for hepatitis C, but this does not indicate which part of the population are carriers and thus 
infective. 
Prevention in Europe 
Half of the countries indicated that they have implemented screening programmes for risk groups: 16 countries 
have programmes for IDUs, 11 for prisoners. It remains unclear whether many countries have implemented 
programmes to monitor the infection rate in healthcare workers. There appears to be a need for more screening 
programmes for risk groups, hard-to-reach populations, and the general population, but before implementing any 
measure a thorough investigation should be carried out, based on a cost-effectiveness analysis and the availability 
of effective treatment.  
Conclusion 
This report collected and analysed data from 29 EU/EEA countries in regard to hepatitis B and C surveillance and 
prevention programmes. Although all countries have systems in place that collect data at the national level, these 
systems differ in the way they apply case definitions and make use of collected data.  
As viral hepatitis is a frequent and often underreported disease, this report tries to summarise the latest available 
prevalence data at EU level. Harmonising the available surveillance data in order to improve comparability of data 
among countries will be a major challenge in the next few years. 
  
 
                                                                    
1 Acute confirmed cases of hepatitis C in France were surveyed only in 2006 and 2007 and for a specific population, 
e.g. HIV-infected men who have sex with men. 
 
 
 
 
TECHNICAL REPORT Surveillance and prevention of hepatitis B and C in Europe 
 
 
 
3 
 
 
 
1 Introduction 
Hepatitis B (HBV) and C (HCV) are viral infections which can cause acute and chronic hepatitis and are the leading 
causes for hepatic cirrhosis and cancer, thus creating a significant burden to healthcare systems due to the high 
morbidity/mortality and costs of treatment. According to the World Health Organization (WHO), one third of the 
world’s population has been infected with HBV, and more than 350 million suffer from chronic infection [i]. 
Approximately 15–40% of infected patients will develop cirrhosis, liver failure or hepatocellular carcinoma. HBV 
accounts for an estimated 600 000 deaths each year, mainly due to the consequences of chronic hepatitis, such as 
cirrhosis and liver cancer [ii
HBV can effectively be prevented by vaccination [
]. The risk of developing a chronic form depends on age at infection: the younger the 
patient, the higher the risk of developing chronic hepatitis: chronic infection is seen in 90% of infants infected at 
birth, 30 to 50% of children infected between the age of one to four years, and 1 to 10% of those infected at older 
age or as adults.  
iii]. A safe and effective HBV vaccine has been available since the 
1980s and can prevent acute and chronic infection with an estimated effectivity of 95% [iv]. In 1992, the WHO 
recommended to implement universal vaccination against hepatitis B for newborns in all countries with an HBV 
prevalence rate higher than 5% in 1995. All other countries were recommended to implement universal vaccination 
in 1997 [v
With regard to HCV, it has been estimated that 170 million persons have chronic infection and that three to four 
million new cases occur each year [
].  
vi]. Initial infection is frequently asymptomatic or mild (70%–90% of cases). Of 
those infected, 50–80% later develop chronic infection, and cirrhosis (up to 50%) and liver cancer (1%–5%) over 
a period of 20 to 30 years. Although other studies show a somewhat lower percentage of cirrhosis and liver cancer 
[vii
There is no vaccine against HCV infection [
], HCV is a major public health problem. A person with HCV can infect others from one to several weeks before 
symptoms. In case of chronic infections, infectivity may persist indefinitely.  
viii]. Research is in progress but the high mutability of the HCV genome 
complicates vaccine development. The greatest impact on HCV disease burden will likely be achieved by focusing 
efforts on reducing the risk of HCV transmission from nosocomial exposures (e.g. screening of blood, rigorous 
implementation of infection control, reducing unsafe injection practices) and high risk behaviours (e.g. injection 
drug use). Relevant measures to reduce transmission are early diagnosis, effective prevention and screening 
programmes, as well as appropriate treatment [ix, x
vi
]. It is known that a large number of people carrying the HCV 
virus are not aware of being infected due to high proportion of asymptomatic infections [ , xi
HBV is transmitted by either percutaneous or mucous membrane contact with infected blood or other body fluid. 
The virus is found in highest concentrations in blood and serous exudates. The primary routes of transmission are 
perinatal, early childhood exposure, sexual contact, and percutaneous exposure to blood or body fluids (i.e. 
injections, needle stick, blood transfusion). Most perinatal infections occur among infants of pregnant women with 
chronic HBV infection. The distribution patterns and risk groups differ widely across the EU. Sexual transmission 
has been estimated to account for 30% to 50% of new infections among adults in industrialised countries. The 
most common risk factors include multiple sex partners and history of a sexually transmitted infection. Finally, 
unsafe injections and other unsafe percutaneous procedures are a major source of blood-borne pathogen 
transmission (HBV, HCV, HIV) in many countries: the risk of HBV infection from needle stick exposure to HBsAg-
positive blood is ~30%. Worldwide, unsafe injection practices account for ~8 to 16 million HBV infections each 
year [
].  
iv]. In the past, HBV was frequently transmitted via blood transfusion, but due to improved testing of blood 
donors the estimated residual risk of acquiring HBV infection via this route ranges from 0.49 to 10 per million 
transfusions in Europe [xxii, xiii, xiv, xv, xvi
In the second half of the 20th century, HCV was transmitted widely through the use of parenteral injections, 
invasive medical and surgical procedures, and transfusion of blood products. An epidemic explosion in IDUs 
followed and for two decades has remained the main transmission route accounting for the majority of new HCV 
infections. The risk for perinatal infections ranges from 3% to 10% in different populations. Sexual transmission is 
thought to be relatively infrequent. However, in many cases, no recognisable transmission factor or route can be 
identified. In Europe, HCV is mainly associated with injecting drug use (blood-to-blood contact, sharing syringes 
and needles), nosocomial transmission, or other parenteral exposure such as needle stick injuries, body piercing or 
tattooing [
].  
xi, xviiixvii, ]. In most countries, injecting drug use accounts for 30% to 60% of all reported HCV cases. 
Another common risk factor is having had a blood transfusion before 1991. In 10% to 54% of cases, the risk factor 
is undetermined or unknown [xix]. It has been observed that high-risk sexual behaviour among (predominantly HIV-
positive) men who have sex with men (MSM) may predispose to HCV infection probably via permucosal route (and 
mucosal damage rather than by sexual contact) [xx, xxi, xxii
xiv
]. The implementation of effective anti-HCV testing 
methods and virus inactivation procedures in the late 1980s and early 1990s, as well as recent introduction of HCV-
RNA tests significantly improved blood transfusion safety [ ]. The estimated residual risk for acquiring HCV via 
blood products ranges from 1 to 40 per 10 million transfusions [x, xiii, xiv, xvi]. Regardless of this improvement, 
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nosocomial transmission of HCV via other routes, such as contaminated substances or multiple dose vials as well as 
via haemodialysis, is still a concern and should be further investigated [xxiii]
In the European Union (EU), the European Economic Area (EEA) and neighbouring countries, the occurrence of 
HBV and HCV is known to differ across countries [
.  
xxiv
Table 1. Number of confirmed cases of hepatitis B reported at EU/EEA level, 2005–07  
]. Between 1995 and 2007, around 83 000 cases of HBV were 
reported at EU/EEA level, but the number of reporting countries varies (AER, ECDC 2009). During this period, a 
steady decrease was observed (see Table 1 below). 
Reporting year Number of HBV cases Reporting countries 
2005 6977 25 
2006 7494 28 
2007 6481 27 
Source: Annual Epidemiological Report on Communicable Diseases in Europe 2009. Stockholm: ECDC; 2009. 
In 2007, 6 481 confirmed cases of hepatitis B virus infections were reported by 27 EU/EEA Member States, giving 
an overall notification rate of 1.5 per 100 000 inhabitants (ECDC 2009). Between 1995 and 2007, almost 310 000 
HCV cases were reported in EU/EEA countries, but it needs to be noted that the number of reporting countries 
varies from one year to another. During this period, a steady increase in the incidence of reported HCV cases was 
observed. In 2007, 27 591 cases of hepatitis C virus infections were reported by 27 EU/EEA Member States and 26 
840 of these were confirmed, giving an overall notification rate of 6.9 per 100 000 inhabitants (ECDC 2009) [xxiv]. 
Over the last few years, HBV incidence has been decreasing while HCV incidence rates have been rising [xxv
The prevalence of HBV and HCV infection varies markedly in different populations. Both diseases are concentrated 
in certain subpopulations such as injecting drug users who have a prevalence rate ten times higher than the 
general population. The prevalence is also higher in men who have sex with men as compared with the 
heterosexual population. In 1999, WHO estimated the worldwide prevalence of HCV at 3%. Most affected areas 
are Africa (5%) and the Eastern Mediterranean region (4.6%), followed by the Western Pacific region (3.9%), and 
South-East Asia (2%). The Americas and Europe had the lowest prevalence estimates, 1.7% and 1%, respectively 
[ xxvii
]. At the 
country level, the incidence of reported cases is variable, and abrupt changes in incidence can be seen. These 
trends probably reflect changes in surveillance systems or prevention activities rather than true changes in 
incidence.  
xxvi]. According to national estimates, 8.8 million (1.3%) people are infected in 22 European countries [ ]
xix
. In 
Europe, the prevalence of HCV can be roughly divided in three patterns: in Northern Europe, the epidemic is 
mainly transmitted by IDU, with overall prevalence rates between 0.1 and 1%. In Central Europe, the HCV 
prevalence is intermediate, ranging from 0.2% to 1.2%. In Southern Europe, the overall prevalence ranges 
between 2.5% and 3.5% [ ]. 
It is obvious that good surveillance data are essential for public health action and planning, as well as policy 
making. In 2006, the harmonisation process of surveillance of viral hepatitis in the EU was identified by the 
European Parliament as one of the priorities for the European Centre for Disease Prevention and Control (ECDC). 
Currently, data is collected by several national surveillance systems but the comparison of these surveillance data 
is hampered by differences in surveillance systems, the population under surveillance, the data sources, and the 
unknown proportion of unreported infections. Also, there is no agreement on practice, need, and usefulness of 
reporting chronic and asymptomatic cases. All in all, there is a clear need to strengthen and harmonise the many 
surveillance systems in Europe.  
ECDC has carried out a survey to map existent national surveillance systems and prevention programmes among 
EU/EEA countries as this would provide an ideal foundation for the development of a protocol for enhanced 
surveillance of hepatitis B and C in the European Union.  
The major objectives of the survey were: 
• to gather detailed information on national surveillance systems and screening programmes for HBV and 
HCV; and 
• to collect information on the national prevention programmes targeting hepatitis B and C. 
The main objective of this study is to provide an overview of existing surveillance systems by not only showing the 
diversity that exists between the countries but also by indicating the potential for ensuring harmonisation and 
consistency. 
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2 Scope and method 
2.1 Survey method and limitations 
All 27 EU Member States and Iceland, Liechtenstein, and Norway were invited to participate in a web-based survey 
on surveillance and prevention of hepatitis B and C. The link to this survey was sent to the nominated contact 
points for hepatitis B and C of the Member States’ competent bodies for surveillance. The survey included separate 
parts for hepatitis B and C. Each questionnaire was divided into four sections: a) general aspects, b) source of data 
collected, c) other questions related to surveillance, and d) prevention. The questionnaires are included in the 
annex to this report.  
Questionnaires were sent in September 2008, and by October 2009 the collected data had been extracted and 
entered in a database. In December 2009, after analysis of the data in Microsoft Excel, the countries’ 
correspondents were asked to update and validate the country-specific data (see Annex 2). All data are available at 
the country level and in an accumulated EU/EEA format. Data collected on vaccination programmes was validated 
and completed with data from the VENICE Project Work Package 1–3 report (www. venice.cineca.org) and EUVAC 
(www.EUVAC.net).  
Also collected were prevalence data on hepatitis B and C in the general population, pregnant women, and IDUs. 
The following limitations of the study must be taken into account:  
• Not all countries answered all questions. 
• Despite an explanatory wordlist issued by ECDC (‘ECDC definitions of some attributes of the surveillance 
systems’), participants understood and interpreted definitions and terminology differently.  
• Blank fields or missing data can only be interpreted as ‘Respondent did not provide requested information in 
the questionnaire’ (unless specified otherwise). This does not necessarily mean that the information is not 
available. 
• Questionnaires that cover a wide range of topics, e.g. surveillance systems, burden of disease, and 
vaccination policies, often generate questions that cannot always be answered. 
• Screening programmes were not defined in detail.  
2.2 Response 
All countries completed both surveys, with the exception of the Czech Republic (only HCV questionnaire) and 
Liechtenstein (only HBV questionnaire). This resulted in a high response rate of 29/30 for each disease. This 
response rate allows us to analyse the collected survey data at the European level. As no overall validation was 
performed, any appraisal of the presented review or inter-country comparison should be performed with caution. 
The respondents and non-respondents by country and disease are shown in Annex 1, Table A1. 
To facilitate the analysis and the comparison between countries, the data for each country is presented in a 
country overview (Annex 2). These profiles consist of two parts: 1) surveillance system, and 2) prevention, and are 
present in a consistent page layout which reflects the questionnaire’s content and wording. A third part on burden 
of disease and epidemiology might be added later, once the surveillance data have been submitted and validated.  
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3 Surveillance systems for HBV and HCV  
All countries have systems for the surveillance and prevention of hepatitis B and C in place, but there are major 
differences in methodology (Table 2). Hepatitis B and hepatitis C surveillance systems are part of the national 
surveillance in all participating countries (29/29). Almost all countries have a mandatory reporting system for HBV 
(93%; 27/29) and HCV (90%; 26/29). Hepatitis C reporting is voluntary in France, Italy, and the United Kingdom; 
hepatitis B reporting is voluntary in Italy and the United Kingdom .   
3.1 Description of surveillance systems 
The vast majority of countries have a passive surveillance system: 90% (25/29) for HBV and 83% (24/29) for HCV.  
There are doubts whether ECDC’s definition of an active surveillance system2
A more detailed analysis of the surveillance systems shows that almost half of the countries (52% or 15/29 for 
HBV, and 48% or 14/29 for HCV) have a country-specific surveillance system in place
 was taken into account when the 
respondent described their national ‘active surveillance systems’ in the questionnaire: in Austria, the Czech 
Republic and Liechtenstein, active surveillance is described as a system which stipulates that physicians or 
laboratories report all suspected or confirmed cases directly to the office of public health; in Slovakia, 
epidemiologists investigate all reported cases (suspected or laboratory-confirmed) and follow up with the patient 
and his direct contacts; and in the United Kingdom, the active surveillance systems for HBV and HCV are described 
as including information from multiple sources. 
3
Sero-surveillance in the general population was reported for six different countries: combined hepatitis B and C 
sero-surveillance was organised in Belgium (one region), France, Slovakia and the United Kingdom; in Germany, 
samples were only tested for hepatitis B, and in the Czech Republic only for hepatitis C (there was no additional 
information available for the United Kingdom). Sero-surveillance studies can contribute to assess the burden of 
disease, as they account for asymptomatic infections as well as chronic infections. Asymptomatic infections are 
often not included in the national surveillance systems. 
. Several countries report 
more than one HBV/HCV surveillance system for their countries; three countries report that, although they have 
several parallel surveillance systems, there is one system that is considered the most comprehensive (HBV in 
France, Spain and the United Kingdom; HCV in Finland, Spain and the United Kingdom). Two countries report that 
several surveillance systems exist, but that none can be seen as dominant (HBV and HCV systems in Belgium; HCV 
systems in France). In five countries (Hungary, Italy, Latvia, Romania and Slovakia), the HBV and HCV reporting 
systems are part of a syndromic surveillance system, which makes it possible to differentiate the reported cases 
according to the aetiology. Seven countries report to collect data on HBV in STI clinics, four report HCV data in STI 
clinics, and seven countries collect data for both HBV and HCV through a laboratory network. Five countries 
perform sero-surveillance in the general population, while only four countries collect data from sentinel surveillance 
systems (Table 3). 
Other country-specific surveillance or screening programmes focusing on risk groups are performed, on a more or 
less regular basis, in Denmark (pregnant women), Finland (IDUs and prisoners), Iceland (alcohol and drug addicts), 
and the United Kingdom (IDUs). Hungary, Iceland and Ireland also consider their national databases for blood and 
blood-borne products as a special surveillance programme for HBV and HCV. In France, the surveillance system for 
HBV and HCV is based on a combination of different screening programmes and sero-surveys. Although other 
HBV/HCV reporting systems are rather rare in the participating countries, they are an important source of data to 
measure the burden of disease in a given country. 
  
 
                                                                    
2 A surveillance system based on a public health officials initiative to contact physicians, laboratory or hospital staff or other 
relevant sources to report data 
3 ‘Own surveillance system’ is considered ‘country-specific’. 
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Table 2. Summary of information on national surveillance systems for Hepatitis B and C  
Information on the national surveillance system according to responses  
from 29 countries, by disease 
Number of countries 
HBV HCV 
Type of surveillance     
  Mandatory 27 26 
  Voluntary 2 3 
  Passive  25  24 
  Active 4 5  
Type of surveillance system     
  Own system 15 14 
  Several surveillance systems, one of which is the most comprehensive 3 3 
  Several surveillance systems, none is the most comprehensive 1 2 
  Syndromic surveillance of viral hepatitis  5 5 
  Other 5 5 
Objectives     
  Monitor trends 29 29 
  Detect outbreaks 26 25 
  Monitor changes in disease distribution 28 27 
  Evaluate and plan control measures 28 28 
  Improve knowledge of epidemiology 27 28 
  Other 5 2 
Case definitions     
  EU 2002/253/EC  3  4 
  EU 2008/426/EC  8 11 
  Possibly EU (lack of information) 5 5 
  Extended EU 5 4 
  No case definition 3 2 
  Other 5 3 
Case classification     
  Possible  1 1 
  Probable 15 6 
  Confirmed 28 28 
  Acute  29 27 
  Chronic 17 18 
  Asymptomatic 9 12 
  Suspected 1 1 
Data collection      
Source of data Physicians 28 28 
  Laboratory 19 19 
  Hospital 19 19 
  Other 4 4 
Availability Case-based 26 26 
  Aggregated 8 9 
Format Electronic 23 25 
  Paper 13 14 
Including duplicates 4 9 
Underreporting No 3 2 
  Exists 26 27 
Frequency of data analysis     
  Daily 5 4 
  Weekly 8 6 
  Biweekly 1 1 
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Information on the national surveillance system according to responses  
from 29 countries, by disease 
Number of countries 
HBV HCV 
  Monthly 10 10 
  Biannually 2 3 
  Yearly 18 19 
Screening programmes     
  Pregnant women 24 3 
  Military recruits 3 1 
  Injecting drug users 15 16 
  STI clinic patients 9 6 
  Multiple sex partners 1 1 
  Prisoners 11 10 
  Haemodialysis patients 20 20 
  Long-term healthcare facilities 2 0 
  Healthcare workers 7 7 
  Workers who are occupationally exposed to the virus 11 9 
  Blood and organ donors 26 27 
Link to other registers     
  Liver transplant 5 5 
  Liver cancer 6 6 
  Mortality 8 8 
  Hospital registers 8 8 
Prevention      
Universal vaccination 22 n/a 
  Infants 11 n/a 
  Adolescents 8 n/a 
  Both 12 n/a 
Risk group vaccination     
  Neonates born to HBsAg+ mothers 21 n/a 
  Individuals at risk for HBV due to occupation 26 n/a 
  Haemodialysis patients 22 n/a 
  Chronic liver disease patients 12 n/a 
  STI clinic patients 10 n/a 
  Multiple sex partners 10 n/a 
  Injecting drug users 17 n/a 
  Household contacts of HBsAg+ patients 22 n/a 
  Contacts of infected persons 17 n/a 
  Other risk groups 12 n/a 
Note: Detailed information on all surveillance systems by country and disease is available in Table A2 (Annex 1). 
 
 
Table 3. Sources for other HBV/HCV surveillance systems  
Number of countries   STI clinic  Laboratory network 
Sentinel 
surveillance 
Sero-surveys in 
general 
population Others 
HBV 9 7 4 5 5 
HCV 6 7 4 5 5 
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3.2 Objectives for hepatitis surveillance 
The national objectives for hepatitis surveillance seem to be very similar in all countries. Almost all predefined 
surveillance objectives in the questionnaires were confirmed by the countries.  
A few countries identified additional surveillance objectives (might be applicable to other countries as well), for 
instance the screening of pregnant women to prevent mother-to-child transmission. Romania added as an 
additional objective ‘to monitor the impact of the universal vaccination programme’, and Slovakia added ‘to 
evaluate existing preventive measures’. Other surveillance objectives identified by Ireland (‘to facilitate resource 
allocation and healthcare planning’; ‘to guide public health action’) and by Luxembourg (‘monthly publication of 
statistics required by law’) are included in the category of country-specific objectives. 
Table 4. Number of countries which have identified objectives for national surveillance  
  Monitoring trends 
Detect  
Outbreaks 
Monitoring changes in 
disease distribution 
Evaluation and 
planning of control 
measures 
Improve 
knowledge of 
epidemiology 
Other 
HBV Yes 29 26 28 28 27 5 No 0 3 (DK, FR, RO) 1 (HU) 1 (LI) 2 (LI, RO) 24 
HCV Yes 29 26  27 28 29 2 No 0 3 (DK, FR, RO) 2 (HU,ES) 1 (ES) 0 27 
Note: The Czech Republic did not participate in the HBV survey; Liechtenstein did not take part in the HCV survey. 
In some countries, surveillance-related activities (organisation of surveillance, case definitions, data collection, data 
format, and frequency of analysis) were not always in line with the official surveillance objectives. For instance, the 
objective ‘outbreak detection’ is very difficult to meet if data are only analysed once a year. Also, ‘planning and 
evaluating control measures’ will be flawed if chronic cases are not included in the surveillance of hepatitis and in 
the case definitions. 
Based on the above results only limited efforts from the countries are needed to harmonise the national 
surveillance objectives with the ECDC long-term surveillance objectives of communicable diseases, 2008–2013 [xxviii]
• Provision of relevant public health data, information and reports to decision-makers, professionals and 
healthcare workers, in an effort to ensure informed decision-making for actions 
: 
• Monitoring of trends in communicable diseases 
• Detection and monitoring of multi-state infectious disease outbreaks 
• Evaluation and monitoring of prevention and control programmes 
• Identification of population groups at risk 
• Contributions to the assessment of the burden of communicable diseases 
• Generation of hypotheses on (new) sources, modes of transmission, and groups most at risk 
3.3 Case definitions  
Although most countries run (national) surveillance systems for HBV and HCV, major differences exist between 
case definitions. It must be noted that the survey was performed in a period when the new EU case definitions4
An analysis of the case definitions used in the surveyed countries shows that 16/29 countries have implemented 
one of the European case definitions for hepatitis B; 20/29 have done so for hepatitis C. Some of them have 
extended the case definitions with extra laboratory criteria; in Romania, France and Ireland not only acute hepatitis 
B cases are reportable but chronic cases with HBsAg persistence in more than six months are included. Portugal 
included probable hepatitis C cases if epidemiologically linked to Laboratory-confirmed cases. The case definition 
for hepatitis C seems to be more harmonised than for hepatitis B; 12/29 countries have implemented the EU 2008 
case definition. In Luxembourg, no case definitions are in place for both hepatitis B and C surveillance; in Lithuania, 
no case definition is in place for hepatitis B. Detailed information on national case definitions is provided for 
hepatitis B (Annex 1, Table A3a) and hepatitis C (Annex 1, Table A3b). 
 
replaced the previous cases definitions (2002/253/EC), effective 1 January 2009. During the validation round for 
country profiles from December 2009 to January 2010, a number of countries took the opportunity to update the 
information on case definitions. 
Two-thirds of the surveyed countries (21/29) use an EU-related case definition for hepatitis B (EU 2002, EU2008, 
possibly EU, EU extended). Over 75% (24 /29) of the countries are using an EU-related case definition for hepatitis 
C, including 11/29 which use the EU 2008 case definition. 
 
                                                                    
4 2008/426/EC: Commission Decision of 28 April 2008 amending Decision 2002/253/EC laying down case definitions for reporting 
communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council 
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3.4 Cases included in hepatitis B reporting 
Case classifications (possible, probable, and confirmed) and stage of infection (chronic and acute) were also 
addressed in the survey. All other countries reported that confirmed cases were included in the surveillance (in 
Belgium, cases are collected based on IgM and/or HBe antigen); half of them also include probable cases. In 
addition to the surveillance based on EU-case definitions, Austria includes ‘suspected’ cases in their national 
surveillance (definition is part of the Austrian approach).  All countries reported that they include acute hepatitis B 
cases in their surveillance systems. National systems were historically based on newly acquired infections in 
patients with clinical symptoms compatible with acute hepatitis. Laboratory reporting made it possible to also 
include asymptomatic individuals with newly acquired infections or newly diagnosed chronic infections. More than 
half of the countries (17/29) reported that they include chronic hepatitis B cases, and about one third (9/29) also 
include asymptomatic cases.  
The majority of the countries that include acute, chronic or asymptomatic cases in the reporting system can also 
distinguish the different stages of infection (14/17). Only Belgium, Iceland and Luxembourg, who only distinguish 
between acute and chronic and/or asymptomatic case, cannot differentiate different stages among confirmed 
cases. Reporting is not always compliant with the national case definition, particularly in respect to case 
classification and stage of infection. This can be illustrated by comparing the results of those countries that report 
data based on EU case definitions (Table 5). Estonia has implemented the EU 2008 case definitions on 1 January 
2009. Although Germany and Romania (Romania has started to implement the EU 2008 case definitions) both use 
the EU 2002 case definition, they do not include probable cases. Among the countries using the EU 2008 case 
definitions, Austria, Latvia, Lithuania and Slovenia also include chronic and/or asymptomatic cases, although these 
cases are not defined in the case definitions. Only Malta, Portugal and Spain (three out of 11 countries that use the 
EU case definitions) report the case classification or stage of infection according to EU case definitions. 
3.5 Cases included in hepatitis C reporting 
All countries report confirmed hepatitis C cases through their national surveillance systems (in Belgium, cases are 
collected based on PCR+). Latvia, Malta, Portugal and Spain include probable cases; in addition to the surveillance 
based on EU-case definitions, Austria includes ‘suspected’ cases in their national surveillance. All countries include 
acute hepatitis C in the national surveillance system except Finland, Norway, Romania (all cases are included, but 
not the different stages of infection) and France (national surveillance was implemented in 2006 and 2007 only, 
targeting a specific population (HIV-infected MSM). Two-thirds (18/29) of the countries reported that they include 
chronic cases of hepatitis C. Although there are no serological markers currently available to accurately 
differentiate between acute and chronic infections, a number of countries indicated that they can differentiate 
these types of infection.  
Hepatitis C reporting is not always compliant with the national case definition, particularly when the EU case 
definitions are used as the basis of national case definitions and for case classification and stage of infection: 
Austria, Latvia, Malta, Poland, Portugal and Spain report probable cases, although they are not mentioned in the 
EU case definitions. Austria also reports possible cases. Lithuania includes asymptomatic cases in its surveillance 
reporting, despite the fact that the EU 2002 case definition is based on clinical symptoms. Half of the countries use 
the EU case definitions (15/29), but in eight countries the reported case classification and stage of infection shows 
discrepancies with the used definition. 
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Table 5. Overview of case classification and the stage of infection used in HBV surveillance system 
compared with EU case definition 
 
 
 
                                                                    
5 Cases are collected based on IgM and/or HBe antigen. 
6 EU 2008 case definition was implemented on 1 January 2009. 
7 Since the early 2000s, several HBV surveillance systems have been implemented at the national level in France, but none is 
based on the EU 2008 acute HBV infection case definition. These systems included the overall and newly diagnosed HBsAg 
screening activity (anonymous screening, laboratory sentinel survey, blood donations) and the surveillance of newly referred 
chronic hepatitis B infected patients in reference centres. Prevalence studies on specific populations (e.g. MSM, drugs users) are 
implemented.  
 Probable Confirmed  Acute Chronic Asymptomatic Differentiated 
2002/253/EC         
2008/426/EC         
Austria        
Belgium5         
Bulgaria        
Cyprus        
Czech Republic        
Denmark        
Estonia6          
Finland        
France7         
Germany        
Greece        
Hungary        
Iceland        
Ireland        
Italy        
Latvia        
Liechtenstein        
Lithuania        
Luxembourg        
Malta        
Netherlands        
Norway        
Poland        
Portugal        
Romania        
Slovakia        
Slovenia        
Spain        
Sweden        
United Kingdom        
Number of countries  15 28  29 17 9  
        
 Included 
 Not included  
 Information not available 
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Table 6. Overview of the case classification and stage of infection used in HCV surveillance system,                                                
compared with the EU case definitions 
 probable confirmed   Acute chronic asymptomatic differentiated 
2002/253/EC N        
2008/426/EC N        
Austria         
Belgium8 N         
Bulgaria N        
Cyprus N        
Czech Republic N        
Denmark N        
Estonia9 N         
Finland N        
France10 N         
Germany N       N 
Greece N        
Hungary N        
Iceland N       N 
Ireland N       N 
Italy         
Latvia         
Liechtenstein        
Lithuania         
Luxembourg         
Malta         
Netherlands         
Norway        N 
Poland         
Portugal         
Romania         
Slovakia         
Slovenia         
Spain         
Sweden N        
United Kingdom N       N 
Number of countries 5 29  27 18 10 9 
 
 
 Included 
 Not included 
 Information not available 
 
It can be concluded that there is a significant heterogeneity between the national surveillance systems for hepatitis 
B and hepatitis C with respect to case definitions and case classification, the reporting of acute and chronic cases, 
and the inclusion of asymptomatic cases. However, a majority of countries already report confirmed case for 
hepatitis B and C, and all countries include acute cases. More than half of the countries (17/29 for hepatitis B, 
18/29 for hepatitis C) include chronic cases although in some cases no differentiation can be made between acute 
and chronic cases. 
 
                                                                    
8 Cases are collected based on PCR+. 
9 Implemented EU 2008 case definition since 1 January 2009. 
10 Surveillance on confirmed acute cases of hepatitis C at the national level was implemented only among HIV-infected MSM and 
only in 2006 and 2007. 
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3.6 Data collection 
Source of data 
Surveillance data for HBV and HCV can originate from multiple and different data sources, like clinicians, 
laboratories, hospitals, municipal health services, and blood banks. In all countries, the clinicians are the most 
important source of data; in the Netherlands, the physicians report their cases to the municipal health services that 
report to the central level. Two-thirds of the countries (19/29) also collect data from laboratories and hospitals. In 
Finland, a parallel system exists for blood banks and antenatal screening (carried out by the same clinicians and 
laboratories): duplicates are later eliminated by means of a unique personal identifier at the national level. 
Germany included additional data from another source but provided no details. Detailed information for every 
country is available in Table A4. 
Collected data 
A ‘basic’ data set is collected in most countries, recording age, gender, place of residence, date of reporting, etc. 
Some countries add variables such as ‘country of birth’ (included by 16 countries) and ‘probable country of 
infection’ (19 countries) (Table 7). Additional epidemiological information is available for a considerable number of 
countries (sexual transmission, drug use, family details, and healthcare-related information). Although some 
countries included ‘changes in disease distribution’ and ‘improved knowledge of epidemiology’ on their list of 
objectives for surveillance, the data needed to meet these objectives (e.g. transmission routes, risk factors and the 
impact of the disease: hospitalisation data, length of hospitalisation, ICD) are not included in the set of variables. 
Detailed information is available in Table A5a for HBV and in Table A5b for HCV. 
Ten countries can link their hepatitis surveillance data to other databases to import or compare data on liver 
transplantations, liver cancer, mortality, and hospital register information (Table 8). Most of these countries 
reported that links are technically possible but not established regularly.  
Format of data 
The majority of countries (90%) collect and provide the surveillance data as individual case based data at central 
level. Only three countries (Bulgaria, Poland and Romania11
Duplicates and underreporting 
) have aggregated data on central level. The majority of 
countries (80%) have implemented electronic disease surveillance systems. Four countries (Bulgaria, Norway, 
Poland and Romania) collect hepatitis C data using a traditional paper-based system, three do the same for 
hepatitis B (Poland, France and Liechtenstein). More information on data formats used in national surveillance 
systems is available in Table A4.  
Five countries (Belgium, Ireland, Luxembourg, Spain, United Kingdom) have indicated that there is a possibility 
that duplicate datasets exist in the national surveillance of hepatitis B and C. An additional four countries also 
mention possible duplicates for hepatitis C (Czech Republic, France, Germany, and Norway). All these countries, 
with the exception of Belgium and France, include the patient ID in the collected surveillance data. In almost all 
countries (HBV 26/29, HCV 27/29) underreporting is a problem in the national surveillance system. The extent of 
underreporting remains unknown for the majority of countries (21 for HBV, 24 for HCV). Two countries report that 
there is probably no underreporting for hepatitis B and C (Iceland, Slovakia). The provided estimates for 
underreporting range from 5% to 6% (Hungary: HBV/HCV) up to 50% (Denmark: HBV/HCV) [xxix
Frequency of analysis 
]. Ireland and the 
UK estimate a 25% underreporting for HBV, and France calculates underreporting at 23% for HBV. No further 
details on the estimates were provided; the differences in underreporting due to the methodology of the 
surveillance or the asymptomatic character of the disease were not addressed.  
More than 60% (HBV 18/29, HCV 19/29) of the countries analyse and report surveillance data at the central and 
national level annually; fewer than half of the countries produce monthly statistics. Portugal, Ireland and the 
United Kingdom provide a quarterly analysis of the data. Austria, Bulgaria, Cyprus, Denmark, Latvia, Slovenia and 
Slovakia have the ability to analyse surveillance data more frequently, even on a daily basis, if need be, for 
example in case of an outbreak. Depending on disease surveillance objectives, the frequency of analysis may have 
to be increased and harmonised across Europe. Detailed information is available in Table A4. 
 
 
 
                                                                    
11 Started to implement case-based data collection since 2009 
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Table 7. Set of variables in national surveillance systems for hepatitis B and C 
  HBV (number of countries) 
HCV 
(number of countries) 
Basic data  Patient ID 24 22 
Date of birth or age 29 29 
Gender 29 29 
Country of birth 16 16 
Place of residence 28 27 
Date of onset of the disease 26 23 
Date of diagnosis 21 21 
Date of reporting/notification 27 28 
Date used for statistics 19 18 
The country where infection most 
likely acquired 19 19 
Immunisation status 24 11 
Outcome 18 15 
Clinical and case classification 
information  
Clinical symptoms 16 13 
Laboratory results 23 24 
Epidemiological information 21 22 
Transmission route/risk factors  Homosexual contact 16 14 
Heterosexual contact 16 13 
Injecting drug use 21 21 
Mother HBsAg/HCV positive 19 15 
Close family member HBsAg/HCV 
positive 20 17 
Sex partner HBsAg+ 17 17 
Blood or blood product transfusion  21 21 
Invasive healthcare procedure/dental 
treatment 18 20 
Organ transplantation 16 17 
Haemodialysis 18 19 
Needle injury or other occupational 
exposure 18 19 
Tattooing/body piercing 18 19 
Other 8 8 
Other factors  Hospitalisation 19 17 
Length of hospitalisation 8 8 
ICD code diagnosis 8 10 
Genotype information 1 3 
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Table 8. Links of surveillance database to at least one other register, by country 
 Liver 
transplant 
Cancer 
of the liver Mortality 
Hospital 
register 
Bulgaria     
Denmark     
Finland     
Iceland     
Lithuania     
Malta     
Romania     
Slovakia     
Sweden     
United Kingdom     
 
3.7 Summary 
Below is a summary of the information provided on national surveillance systems for hepatitis B and C in the EU 
and EEA countries. 
Major similarities: 
• All countries have surveillance in place for both hepatitis B and C. 
• A majority of surveyed countries operates a passive mandatory hepatitis surveillance system. 
• National objectives for surveillance are very similar in all countries. 
• Although there is a wide variety in case definitions, most Member States include confirmed and acute cases 
in their reporting system. 
• Clinicians are the major source of data for the surveillance systems. 
• 80% of the surveyed countries have case-based data available, at the national level and in an electronic 
database. 
• A basic set of data (age, gender, place of residence, date of onset of disease, and date of reporting) is 
collected in most countries. 
• Underreporting is common, but to an unknown extent. Duplicates are rather uncommon. 
Major differences: 
• The administration of disease surveillance for hepatitis B and C varies widely across countries, e.g. there is 
a wide range of case definitions and case classifications. It needs to be noted that the EU case definitions 
are not consistently implemented. 
• Chronic and asymptomatic cases are often not included in the surveillance data. 
• The frequency of data analysis and data reporting varies across countries. 
• There is a wide variety in the set of variables collected, particularly in respect to epidemiological risk factors 
and the impact of the disease (length of hospitalisation, ICD code). 
• A number of Member States have the possibility to link hepatitis surveillance to other registers of morbidity 
and mortality. 
The surveillance of hepatitis B and hepatitis C is mostly mandatory in EU/EEA countries; more countries tend to 
use the EU 2008 case definition for hepatitis C than for hepatitis B. 
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4 Prevention programmes for HBV and HCV  
4.1 Screening programmes  
In all countries except Luxembourg at least one screening programme is in place for HBV or HCV. Screenings for 
hepatitis B virus infections in pregnant women are conducted in more than 80% (24/29) of the countries, while in 
Bulgaria, Lithuania, Luxembourg, and Romania this programme is not implemented; in Belgium12
Blood and organ donors and haemodialysis patients are also screened in most countries, except for Iceland (HBV in 
blood and organ donors), Liechtenstein (HBV, HCV), Luxemburg (HBV, HCV) and Finland (HBV in haemodialysis 
patients). In Austria, Denmark, Estonia, Netherlands, and Romania, haemodialysis patients are not screened for 
HBV and HCV. Half of the countries conduct hepatitis B screening programmes for specific groups at risk, e.g. 
injecting drug users (15/29), STI clinic patients (9/29), and prisoners (11/29). Two countries operate a programme 
for persons with multiple sex partners (2/29)
 the programme is 
not implemented at the national level.  
13
Table 9. Antenatal screening programmes for hepatitis B and C in Europe, 2009 
.  
 HBV HCV 
Austria   
Belgium12   
Bulgaria   
Cyprus   
Czech Republic   
Denmark   
Estonia   
Finland   
France   
Germany   
Greece   
Hungary   
Iceland   
Ireland   
Italy   
Latvia   
Liechtenstein   
Lithuania   
Luxembourg   
Malta   
Netherlands   
Norway   
Poland   
Portugal   
Romania   
Slovakia   
Slovenia   
Spain   
Sweden   
United Kingdom   
 
 Programme implemented 
 No programme 
 Not applicable 
 
 
                                                                    
12 Belgium: Screening for HBV among pregnant women is recommended; a vaccination programme for neonates born from 
HBsAg-positive mothers exists. 
13 Ireland: Only if the person attended as a patient of an STI clinic. 
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Specific screening programmes target multiple risk groups. Screening of healthcare workers for hepatitis B is 
implemented in six countries (Belgium, France, Germany, Italy, Malta, and Romania). An additional eight countries 
(Hungary, Ireland, Latvia, Lithuania, Poland, Portugal, Spain, and the United Kingdom) indicated that they run a 
screening programme for ‘workers who are occupationally exposed to the virus’.  
Screening programmes which target injection drug users (IDUs) or prisoners usually include both hepatitis B and C 
infections, except in France where IDUs are only screened for hepatitis C. Cyprus, Germany, Malta, Romania, 
Slovakia, and Spain have an HCV screening programme in STI clinics; Germany operates an HCV screening 
programme for persons with multiple sex partners. Detailed information on all screening programmes is provided in 
Table A6a for hepatitis B and Table A6b for hepatitis C. 
4.2 Immunisation programmes for hepatitis B 
Hepatitis B vaccination has shown to be effective in the reduction of new infections. The vaccine is 95% effective 
in preventing infection and its chronic consequences and has an outstanding record of safety and effectiveness [iv].  
Universal HBV vaccination 
In 1991, WHO advised all countries to add Hepatitis B inoculation to in all universal vaccination programmes. A 
number of countries have not complied with this recommendation, based on their national epidemiological situation. 
Seven countries (Denmark, Finland, Iceland, the Netherlands, Norway, Sweden, and the United Kingdom) have 
opted for a selective hepatitis B vaccination programme targeting risk groups. 22 out of 29 EU/EEA countries have 
implemented a universal vaccination programme for infants and adolescents or both, in addition to a selective 
immunisation programme (Table 9). In Slovenia, a universal vaccination programme exists for children before 
entering primary education.  
Table 10. Universal vaccination programmes for HBV in 29 EU/EEA countries  
 Universal vaccination programmes 
 Universal Infants Adolescents Other Adolescents (catch up) 
Austria      
Belgium      
Bulgaria      
Cyprus      
Czech Republic No information available  
Denmark      
Estonia      
Finland      
France      
Germany      
Greece      
Hungary      
Iceland      
Ireland      
Italy      
Latvia      
Liechtenstein      
Lithuania      
Luxembourg      
Malta      
Netherlands      
Norway      
Poland      
Portugal      
Romania      
Slovakia      
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 Universal vaccination programmes 
 Universal Infants Adolescents Other Adolescents (catch up) 
Slovenia      
Spain      
Sweden      
United Kingdom      
 
 Vaccination programme (as of 2009) 
 No vaccination programme  
 No universal vaccination programme 
 
Although the majority of countries have included hepatitis B in their universal vaccination programmes, the 
programmes are heterogeneous and show a wide variation in immunisation schedules (timing and number of doses) 
and vaccine formulation (monovalent, hexavalent) exists. Countries with a neonatal vaccination programme 
integrated in the universal vaccination programme have comparable schedules. In addition to the routine childhood 
vaccination programme for newborns or infants, catch-up programmes for older children and adolescents were also 
carried out in Austria, Belgium, Cyprus, France, Germany, Greece, Hungary, Italy, Latvia, Liechtenstein, Romania, 
and Slovenia.  
Risk group vaccination 
In addition to their universal vaccination programmes, most countries have implemented additional programmes 
for risk groups, usually for those at increased risk of acquiring HBV via occupational exposure (26/29). Vaccination 
programmes for neonates born to HBsAg-positive mothers (21/29), haemodialysis patients (22/29), and household 
contacts of HBsAg-positive patients (22/29) are implemented in at least 70% (23/29) of the countries. 23 countries 
(79%) also have vaccination programmes for HBV among IDUs.  
Table 11. Risk group vaccination programmes for HBV in 29 EU/EEA countries  
   Risk group vaccination 
 
un
iv
er
sa
l Neonates 
born to 
HBsAg + 
mothers 
Individuals at 
risk for HBV 
due to 
occupation 
Haemodialys
is 
patients 
Chronic 
liver 
disease 
patients 
STI clinic 
patients 
Persons 
with 
multiple 
sex 
partners 
Injecting 
drug 
users 
Household 
contacts of 
HBsAg+ 
patients 
Contacts 
with 
infected 
persons 
Other 
risk 
groups 
Austria            
Belgium            
Bulgaria            
Cyprus            
Czech Republic  No information available       
Denmark            
Estonia            
Finland            
France            
Germany            
Greece            
Hungary            
Iceland            
Ireland            
Italy            
Latvia            
Liechtenstein            
Lithuania            
Luxembourg            
Malta            
Netherlands            
Norway            
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   Risk group vaccination 
 
un
iv
er
sa
l Neonates 
born to 
HBsAg + 
mothers 
Individuals at 
risk for HBV 
due to 
occupation 
Haemodialys
is 
patients 
Chronic 
liver 
disease 
patients 
STI clinic 
patients 
Persons 
with 
multiple 
sex 
partners 
Injecting 
drug 
users 
Household 
contacts of 
HBsAg+ 
patients 
Contacts 
with 
infected 
persons 
Other 
risk 
groups 
Poland14             
Portugal            
Romania            
Slovakia            
Slovenia            
Spain            
Sweden            
United 
Kingdom 
           
No countries  22 27 23 14 11 11 18 23 18 12 
 
 Universal vaccination programme (as of 2009) 
 No universal vaccination programme 
 
Countries without universal vaccination programmes (Denmark, Finland, Iceland, Netherlands, Norway, Sweden, 
and the United Kingdom) or countries which recently added hepatitis B vaccination to their routine vaccination 
programme (Ireland) for the most part have extensive vaccination programmes for risk groups. All countries have 
at least one hepatitis B prevention programme (Table 11). Exceptions are Austria and Liechtenstein, where 
vaccination is offered only in universal programmes. 
Specific risk group vaccination programmes focus on thalassaemia (Belgium), blood and organ transplantation 
(Belgium), mentally disabled people or Down’s syndrome (Belgium, France, Netherlands), HIV infection (Bulgaria, 
Poland), MSM (Denmark, Norway, Netherlands, United Kingdom), prisoners (France, Ireland, United Kingdom), 
social workers (Netherlands), newborns with at least one parent from an HBV-endemic country (Netherlands, 
Norway), migrants from countries with medium to high endemicity (Norway), sex workers (Norway), patients 
infected with other types of hepatitis (Slovakia). Most frequently mentioned are travellers to countries with a high 
prevalence of hepatitis B (Belgium, Bulgaria, France, Germany, Ireland, United Kingdom). 
Vaccination coverage 
More than half of the countries with a universal vaccination programme calculated and reported vaccine coverage. 
In general, the coverage for infant vaccination programmes is rather high (on average above 90%). Belgium, 
Bulgaria, Estonia, Italy, Latvia, Lithuania, Poland, Romania, Slovakia, and Spain report coverage rates in infants 
younger than two years that surpass 95%. Austria, Malta and Portugal report a coverage rate of 30%, 76% and 
97%, respectively, in one-year-old infants. In Austria, the coverage rate in infants of two years is 83%, France 
reports 35% for the same age group.  
  
 
                                                                    
14 Vaccination recommended for STI clinic patients, persons with multiple sex partners, injecting drug users. 
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Map 1. Reported hepatitis B vaccination coverage rate in infants of one to two years  
 
 
Map 2. Reported hepatitis B vaccination coverage rate in adolescents 10 to 15 years  
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The coverage rate in adolescents is generally lower than in infants, except for Estonia, Poland, Romania and 
Slovakia. Hungary, which includes the inoculation of 14-year-olds in the routine vaccination programme, reports a 
coverage rate between 95% and 98%. Despite the catch-up programmes in France, Italy, and Latvia, the coverage 
rates in the 14- to 15-year-olds are considerably lower at 42%, 80%, and 74%, respectively. In Austria, the 
coverage rates in adolescents vary between 24% for 11-year-olds and 43% for 14-year-olds. In Greece and Spain, 
the coverage rates are below 90%: 87% (15-year-olds, Greece) and 78% (14-year-olds, Spain).  
Summary 
Prevention programmes for hepatitis B and C in the surveyed EU/EEA countries can be summarised as follows: 
• Most countries have at least one screening programme in place for HBV or HCV. 
• Blood and organ donor screening programmes are implemented in most Member States, as this is required 
by EU legislation. 
• Almost all countries recommend the screening of pregnant women, except for some countries which have 
included the vaccination of neonates in their routine vaccination programmes. 
• 22 out of 29 Member States included hepatitis B in the routine childhood vaccination programme. Seven 
countries do not vaccinate children routinely and use selective immunisation programmes instead. 
• Hepatitis B vaccination is recommended in almost all Member States for those individuals at increased 
occupational risk. 
• Risk group vaccination programmes vary widely across countries. 
• The reported coverage rates are heterogeneous, but for most countries with a routine vaccination 
programme the coverage rate in infants is above 95%. 
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5 Epidemiology 
5.1 Hepatitis B 
The number of reported cases per 100 000 population varies widely across countries. In 2007, Denmark, Finland, 
France, Greece, Malta, Poland, Portugal, and Slovenia reported an incidence lower than 1 per 100 000 (Slovenia 
included chronic cases in the data). Cyprus, Germany, Ireland, Italy, Lithuania, the Netherlands, Slovakia, Spain, 
and Sweden reported a slightly higher incidence rate: 1 to 2.5 cases per 100 000. Relatively high incidence rates 
were reported by Latvia (7.2), Austria (7.8), and Bulgaria (9.8). The highest incidence rate was reported by Iceland 
(15/100 000), which can partly be explained by the fact that Iceland included chronic hepatitis B cases. 
The difference in hepatitis B incidence rates across Europe could be partly due to differences in case definitions 
and classifications, and requires further investigations. Comparability can be improved through harmonisation of 
datasets, e.g. by distinguishing between acute and chronic hepatitis, or using a uniform case definition for 
laboratory-confirmed cases. A major challenge is the possibility to distinguish between acute and chronic cases, as 
the current data for most countries represent a mixture of acute and chronic cases.  
 
Figure 1. Number of reported hepatitis B cases per 100 000 population in the 29 EU/EEA countries, 
2007  
 
Acute and chronic cases included for AT, BE, IS, LU, PL, SL 
Source: ECDC Annual Epidemiological Report 2009 
Prevalence data on HBsAg in the general population were limited, ranging from 3.8% in Bulgaria to 0.01% in 
Denmark: Slovakia (1.6%); Italy (1%); Belgium and France (around 0.6 %); Finland, Hungary and the United 
Kingdom (>0.5%) (Table 12). According to the predefined HBsAg prevalence ranges for HBV infection – high 
(>8%), intermediate (2-8%), and low (<2%) – all reporting countries can be classified as low-prevalence countries, 
with the exception of Bulgaria which ranks as intermediate. 
The variation in HBsAg prevalence in pregnant women is less distinct and varies between 1.15% (Greece) and 0.15% 
(Finland), while the prevalence in IDUs is higher and ranges between 0.5% in Norway and 50% in Denmark (2007 
data). In most countries, the trend in reported hepatitis B cases seems to be decreasing, except for Cyprus, 
Iceland, Luxembourg, and Sweden. Abrupt changes in the number of reported HBV cases may have several causes: 
a change in the surveillance system (Lithuania) or an outbreak among IDUs (Latvia 1999–2002). Further 
investigations of the trends in connection with changes in surveillance systems are needed. Most European 
countries seem to have a low incidence, below 5 cases per 100 000 population. The inclusion or exclusion of 
chronic cases in the reported surveillance data affects trends noticeably, as can be seen in Bulgaria, the 
Netherlands, Poland, and Sweden. The implementation of enhanced surveillance for hepatitis B will further improve 
the comparability of reported cases across EU/EEA countries.  
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Table 12. HBV prevalence (HBsAg) per 100 000 population, 29 EU/EEA countries: general population, 
pregnant women, and IDUs 
HBV 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 
General population 
Belgium         0.66%           
Bulgaria     3.80%               
Denmark                 0.01% 0.01% 
Finland             0.23%       
France           0.65%         
Hungary   0.30%                 
Italy                 1.00%   
Slovakia       1.60%             
Sweden 0.03% 0.04% 0.04% 0.05% 0.03% 0.03% 0.05% 0.04% 0.03% 0.02% 
United 
Kingdom 
0.37%                   
Pregnant women 
Czech 
Republic 
  0.20%        
Denmark                 0.26% 0.26% 
Estonia               0.30% 0.20%   
Finland             0.10% 0.14%     
Greece           1.15%         
Italy                 0.86%   
Netherlands               0.40% 0.34% 0.33% 
United 
Kingdom 
                0.31% 0.35% 
Injecting drug users 
Bulgaria               5.63%     
Cyprus               2.08% 7.80%   
Denmark                 50.00% 50.00% 
France           1.91%         
Greece         2.3%-5.8%           
Italy                   13.70% 
Norway       3.00% 4.00% 3.00% 0.80% 0.90% 0.50% 1.20% 
Poland                 5.00%   
Slovenia         10.40%           
Sweden          1% 
5.2 Hepatitis C  
There is a wide variety in reported data since hepatitis C is often asymptomatic and no clear diagnostic criteria are 
available to differentiate between acute and chronic cases. The diversity in reported data was higher than for 
hepatitis B. The HCV incidence rate in 2007 varies between 36.7 cases per 100 000 (Ireland) and 0.05 (Greece). 
Countries which reported only acute hepatitis C cases in 2007, had an incidence rate below 1.4 cases/100 000; 
with Estonia as the sole exception (2.7/100 000). Countries which included chronic cases displayed much higher 
incidence rates: Iceland (31), Ireland (36.7), and Sweden (20.6) report incidences above 20/100 000.  
As is the case with hepatitis B, the presented data for hepatitis C are difficult to interpret because of differences in 
surveillance systems, case definitions, etc., and any interpretation or comparison should be conducted with caution. 
Trends in HCV incidence data suggest an increasing trend over time. 
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Figure 2. Number of reported hepatitis C cases per 100 000 population in the 29 EU/EEA countries, 
2007 
 
Acute and chronic cases included for AT, DE, IS, LI, MT, NO, SL, ES 
Source: ECDC Annual Epidemiological Report 2009 
HCV prevalence data are available for the general population (nine countries) and injection drug users (11 
countries) (Table 13). The prevalence in the general population ranges from 2.6% in Italy (2007) to 0.12% in 
Belgium (2003). In 2001, the Czech Republic and the Netherlands reported prevalence below 0.5%, while Bulgaria 
reported a prevalence of 1.2% in the general population. There is a wide variety in the reported HCV prevalence in 
IDUs, ranging from 25% to 70%. Of the seven countries reporting HCV prevalence in IDUs between 2006 and 
2008, Italy reported the lowest prevalence (10.8–25.6%), and Norway the highest (70%).  
HCV prevalence among national samples of injecting drug users vary from around 10% to 95%, with half of the 
countries reporting levels in excess of 40%. Slovenia reported prevalence below 25% in national samples of 
injecting drug users. HCV prevalence levels can vary considerably within a given country, reflecting both regional 
differences and the characteristics of the sampled population. For example, in the United Kingdom local studies 
report levels between 29% and 60%, while in Italy different regional estimates range from around 36% to 92%.  
For 2006–08, three of the ten countries providing data on injecting drug users report a HCV prevalence of more 
than 40% (xxx
 
). 
Table 13. HCV prevalence per 100 000 population, 29 EU/EEA countries: general population, 
pregnant women, and IDUs 
HCV 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 
General population 
                   
Belgium           0.12%           
Bulgaria       1.20%               
France             0.84%         
Hungary     0.70%                 
Italy                   2.60%   
Netherlands       0.40%               
Slovakia         1.52%             
Sweden  0.13% 0.13% 0.09% 0.09% 0.08% 0.06% 0.08% 0.05% 0.07% 0.04% 
United 
Kingdom 
          0.50%           
Injecting drug users           
Belgium               50.00%       
Bulgaria                   57.01%   
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HCV 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 
Cyprus                 29.59% 34.31%   
Denmark                   70.00% 70.00% 
Finland               53.00%   57.00%   
France             59.80%         
Greece         43.3%-61.7%             
Italy                     10.8–25.6% 
Norway         79.00% 74.00% 68.00% 69.00% 70.00% 64.00% 68.40% 
Slovenia         21.00% 22.50%           
Sweden           83% 
United 
Kingdom 
41.00% 35.00% 35.00% 36.00% 39.00% 42.00% 41.00% 42.00% 41.00% 39.00% 40.00% 
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6 Discussion and conclusion 
Viral hepatitis has a significant impact on national healthcare systems. Without monitoring hepatitis B and C it 
would be impossible to contribute to the various prevention and control programmes, or gain an understanding of 
the magnitude of the problem. This report presents a broad overview of national surveillance systems and 
prevention programmes for hepatitis B and C in EU/EEA Member States. 
All countries have national surveillance systems for HBV and HCV in place, with very similar objectives but the 
attributes of the surveillance systems are very heterogeneous. Differences exist with respect to case definitions; 
the inclusion of possible, probable and confirmed cases; the inclusion of acute, chronic and asymptomatic cases; 
and on the question whether a distinction can be made between these types. Ideally, a case definition for hepatitis 
should include a clinical description, laboratory criteria, and a case classification – possible, probable and confirmed. 
This issues need to be addressed when developing an enhanced surveillance protocol.  
Most countries collected a basic set of data (patient ID, date of birth, gender, place of residence, date of reporting, 
immunisation status), but detailed data on risk factors or the source of infection are missing. This type of 
information is crucial for informing and guiding prevention policies, and should be added soon.  
Data on the impact of the disease (hospitalisation data, length of hospitalisation, and ICD) are crucial for burden of 
disease and healthcare studies and should be discussed as well. The interpretation of incidence and prevalence 
data for hepatitis B and C is hampered by the many differences between the current surveillance systems, which 
use different case definitions, survey different population segments, obtain data from different sources, and leave 
an unknown percentage of infections unreported. An inter-country comparison of these data is difficult and should 
be conducted with caution and preferably only on data on trends.  
Enhanced surveillance of hepatitis B and C at the EU level should provide added value by collecting more reliable 
and comparable data across countries, in order to accurately compare trends in hepatitis B and C and monitor risk 
groups across countries. A major challenge is the case-based surveillance of hepatitis C. It is currently not possible 
to differentiate between acute and chronic cases, which will hamper the correct interpretation of future surveillance 
data.  
Hepatitis B vaccination programmes are conducted in all countries. 22 countries have included HBV vaccination in 
their routine vaccination programmes, and a further seven countries have implemented selective vaccination 
programmes targeted at risk groups. Vaccination coverage could be improved in some countries, ranging from 30% 
to 100% in infants. To evaluate vaccination strategies, studies on surveillance, sero-epidemiology and coverage 
need to be harmonised and thus become comparable. In general, prevention strategies at the European level 
would benefit from further harmonisation. 
We conclude that harmonisation of EU surveillance represents an added value as it makes it possible to assess the 
disease burden, evaluate prevention and control strategies, and define epidemiological trends or transmission 
patterns. The results of this survey will be used to strengthen the enhanced surveillance of hepatitis B and C at the 
EU level.  
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Table A1. Overview of participating EU/EEA countries in the HBV and HCV surveillance and 
prevention survey 
  HBV HCV 
Austria AT   
Belgium BE   
Bulgaria BG   
Cyprus CY   
Czech Republic CZ    
Denmark DK   
Estonia EE   
Finland FI   
France FR   
Germany DE   
Greece GR   
Hungary HU   
Iceland IS   
Ireland IE   
Italy IT   
Latvia LV   
Liechtenstein LI    
Lithuania LT   
Luxembourg LU   
Malta MT   
Netherlands NL   
Norway NO   
Poland PL   
Portugal PT   
Romania RO   
Slovakia SK   
Slovenia SI   
Spain ES   
Sweden SE   
United Kingdom UK   
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Table A2. Summary of existing surveillance systems in the 29 EU/EEA countries 
 HBV HCV 
 In national 
surveillanc
e system 
Man-
da- 
tory 
Passive or 
other 
Surveillance system In national 
surveillanc
e system 
Man-
da- 
tory 
Passive or other Surveillance 
system 
  
Austria Yes Yes Active: Every 
physician has 
to report 
suspected and 
confirmed 
cases and 
deaths. 
Laboratories 
are included in 
the mandatory 
reporting 
system. 
Other Laboratory-
confirmed cases 
Yes Yes Active: Every 
physician has to 
report suspected 
and confirmed 
cases and deaths. 
Laboratories are 
included in the 
mandatory 
reporting system. 
Other Laboratory-
confirmed 
cases 
Belgium Yes Yes Passive Several 
surveillance 
systems for 
HBV, of which 
no single 
system is the 
major one  
(please 
describe below) 
Mandatory 
notification 
 
Sentinel 
laboratory 
Yes Yes Passive Several 
surveillance 
systems for 
HCV, of 
which no 
single 
system is 
the major 
one  
(please 
describe 
below) 
Mandatory 
notification 
 
Sentinel 
laboratory 
Bulgaria Yes Yes Passive Own system for 
HBV 
  Yes Yes Passive Own 
system for 
HCV 
  
Cyprus Yes Yes Passive Other (*) Yes Yes Passive Other (*) 
Czech 
Republic 
No results available Yes Yes Active: Physicians 
report to PHC 
Own 
system for 
HCV 
  
Denmark Yes Yes Passive Own system for 
HBV 
  Yes Yes Passive Own 
system for 
HCV 
  
Estonia Yes Yes Passive Other HBV is a 
notifiable 
disease. 
Information is 
provided by 
GPs, hospitals, 
and 
microbiological 
laboratories. 
Surveillance of 
HBV is a part of 
the national 
surveillance 
system. 
Yes Yes Passive Other HCV is a 
notifiable 
disease. 
Information is 
provided by 
GPs, hospitals 
and micro-
biological 
laboratories. 
Surveillance of 
HCV is a part 
of the national 
surveillance 
system. 
Finland Yes Yes Passive Own system for 
HBV 
Part of the 
general 
surveillance 
system for 
infectious 
diseases; part of 
the screening 
programme for 
expecting 
mothers 
Yes Yes Passive Several 
surveillance 
systems for 
HCV, one 
of which is 
the major 
and most 
comprehen
sive one. 
The main 
system is the 
National 
Infection 
Register, 
which is the 
mandatory 
system for 
notifiable 
diseases. 
The 
secondary 
system is a 
sampling- 
based, 
anonymous 
prevalence 
estimation 
system for 
injecting drug 
users which 
functions as a 
sentinel 
surveillance 
system. This 
is carried out 
every one to 
two years 
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 HBV HCV 
 In national 
surveillanc
e system 
Man-
da- 
tory 
Passive or 
other 
Surveillance system In national 
surveillanc
e system 
Man-
da- 
tory 
Passive or other Surveillance 
system 
  
France Yes Yes Passive Several 
surveillance 
systems for 
HBV, one of 
which is the 
major and most 
comprehensive 
one 
Mandatory 
reporting of 
acute hepatitis B  
 
Chronic cases: 
seroprevalence 
surveys, lab and 
reference 
sentinel 
systems, blood 
donor 
surveillance 
Yes Volun- 
tary 
Active: Depends on 
surveys 
Several 
surveillance 
systems for 
HCV, of 
which no 
single 
system is 
the major 
one  
(please 
describe 
below) 
Lab activity 
for HCV 
screening 
 
HCV 
prevalence 
surveys (drug 
users, HIV+, 
MSM, general 
population) 
 
HCV sero-
conversion 
surveys: 
blood donors, 
occupationally 
acquired 
infections in 
HCW, 
accidental 
exposures in 
HC settings 
 
Newly 
referred 
HCV+ 
patients in 
hepatology 
centres 
Germany Yes Yes Passive Own system for 
HBV 
  Yes Yes Passive Own 
system for 
HCV 
  
Greece Yes Yes Passive Own system for 
HBV 
  Yes Yes Passive Own 
system for 
HCV 
  
Hungary Yes Yes Passive HBV reporting 
is included in 
syndromic 
surveillance of 
viral hepatitis 
  Yes Yes Passive HCV 
reporting is 
included in 
syndromic 
surveillance 
of viral 
hepatitis 
  
Iceland Yes Yes Passive Own system for 
HBV 
  Yes Yes Passive Own 
system for 
HCV 
  
Ireland Yes Yes Passive Own system for 
HBV 
  Yes Yes Passive Own 
system for 
HCV 
  
Italy Yes Volun- 
tary 
Passive HBV reporting 
is included in 
syndromic 
surveillance of 
viral hepatitis 
(**) Yes Volun- 
tary 
Passive HCV 
reporting is 
included in 
syndromic 
surveillance 
of viral 
hepatitis 
(**) 
Latvia Yes Yes Passive HBV reporting 
is included in 
syndromic 
surveillance of 
viral hepatitis 
  Yes Yes Passive HCV 
reporting is 
included in 
syndromic 
surveillance 
of viral 
hepatitis 
  
Liechten-
stein 
Yes Yes Active: The 
laboratories 
report every 
positive HBV-
test to the 
Office for 
Public Health 
and the office 
makes further 
inquiries. 
Own system for 
HBV 
  No results available 
Lithuania Yes Yes Passive Own system for 
HBV 
  Yes Yes Passive Own 
system for 
HCV 
  
Luxem-
bourg 
Yes Yes Passive Other HBV notified via 
mandatory 
notification 
system 
Yes Yes Passive Other HBC notified 
via mandatory 
notification 
system 
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 HBV HCV 
 In national 
surveillanc
e system 
Man-
da- 
tory 
Passive or 
other 
Surveillance system In national 
surveillanc
e system 
Man-
da- 
tory 
Passive or other Surveillance 
system 
  
Malta Yes Yes Passive Own system for 
HBV 
  Yes Yes Passive Own 
system for 
HCV 
  
Nether-
lands 
Yes Yes Passive Own system for 
HBV 
  Yes Yes Passive Own 
system for 
HCV 
  
Norway Yes Yes Passive Own system for 
HBV 
  Yes Yes Passive Own 
system for 
HCV 
  
Poland Yes Yes Passive Own system for 
HBV 
System is 
integral part of 
the national 
communicable 
disease 
surveillance 
system 
Yes Yes Passive Own 
system for 
HCV 
System is 
integral part 
of the national 
communicable 
disease 
surveillance 
system 
Portugal Yes Yes Passive Other Included in the 
national 
mandatory 
surveillance 
system for 
communicable 
diseases 
Yes Yes Passive Other One 
mandatory 
surveillance 
system for 
several 
communicable 
diseases, 
including 
acute 
hepatitis C. 
 
Hepatitis C 
reporting 
system is 
called PT-HCV 
Romania Yes Yes Passive HBV reporting 
is included in 
syndromic 
surveillance of 
viral hepatitis 
  Yes Yes Passive HCV 
reporting is 
included in 
syndromic 
surveillance 
of viral 
hepatitis 
  
Slovakia Yes Yes Active: Slovak 
epidemiologists 
investigate 
each reported 
suspect case or 
each laboratory 
positive result 
directly with 
patient and her 
or his direct 
contacts 
HBV reporting 
is included in 
syndromic 
surveillance of 
viral hepatitis 
  Yes Yes Active: Any suspect 
case of viral 
hepatitis is 
investigated by 
epidemiologists 
HCV 
reporting is 
included in 
syndromic 
surveillance 
of viral 
hepatitis 
  
Slovenia Yes Yes Passive Own system for 
HBV 
  Yes Yes Passive Own 
system for 
HCV 
  
Spain Yes Yes Passive Several 
surveillance 
systems for 
HBV, one of 
which is the 
major and most 
comprehensive 
one 
  Yes Yes Passive Several 
surveillance 
systems for 
HCV, one 
of which is 
the major 
and most 
comprehen
sive one 
HCV is 
included in 
the syndromic 
surveillance of 
viral hepatitis. 
In addition, 
data on HCV 
are collected 
through a 
voluntary 
reporting 
system based 
on reports 
sent by the 
microbiology 
laboratories in 
hospitals (see 
supplemen-
tary 
information at 
the end of the 
questionnaire) 
Sweden Yes Yes Passive Own system for 
HBV 
SmiNet Yes Yes Passive Own 
system for 
HCV 
SmiNet 
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 HBV HCV 
 In national 
surveillanc
e system 
Man-
da- 
tory 
Passive or 
other 
Surveillance system In national 
surveillanc
e system 
Man-
da- 
tory 
Passive or other Surveillance 
system 
  
United 
Kingdom 
Yes Volun- 
tary 
Active: 
Includes 
information 
from multiple 
sources 
(primarily the 
laboratory 
carrying out 
the testing) to 
detect 
changing 
patterns in 
hepatitis B. 
Blood 
specimens are 
tested to 
determine 
acute hepatitis 
B infection. 
Several 
surveillance 
systems for 
HBV, one of 
which is the 
major and most 
comprehensive 
one. 
  Yes Volun- 
tary 
Active: Includes 
information from 
multiple sources, 
including the 
microbiology 
laboratory, to detect 
changing patterns 
of hepatitis C 
infection.  
Blood specimens 
are tested to 
determine hepatitis 
C exposure. 
Several 
surveillance 
systems for 
HCV, one 
of which is 
the major 
and most 
comprehen
sive one. 
  
 
(*) Cyprus: 57 communicable diseases are mandatorily notified to the Director of Medical and Public Health Services (MPHS) by 
all practising medical doctors (See Quarantine Law and its amendments.) Reporting is done by completion of a specific 
form which is submitted to the District Medical Officer who forwards it to the Unit for Surveillance and Control of 
Communicable Diseases (MPHS Central Offices). For a number of diseases (i.e. plague, yellow fever, cholera, 
meningococcal meningitis) notification is within 24 hours and simultaneously to the District Medical Officer and the Director 
of Medical and Public Health Services. Data are entered in a database (EPI-INFO) and analysed. 
(**) Italy: The national surveillance system for acute viral hepatitis infection (SEIEVA, Sistema Epidemiologico Integrato 
dell’Epatite Virale Acuta), coordinated by the National Centre for Epidemiology, Surveillance and Health Promotion of the 
Istituto Superiore di Sanità, has as the main goal to promote the monitoring and control of acute viral hepatitis infection at 
the local and national levels. Epidemiological data are combined with laboratory data to estimate the impact of various risk 
factors, allowing prevention programmes to be defined and evaluated. Specific goals of the surveillance are: 
• to determine the number of cases of acute viral hepatitis infection, by specific type of infection; 
• to calculate the incidence of acute viral hepatitis infection, by type of infection, date and place of disease onset, age, 
and gender; 
• to identify outbreaks in a timely manner; 
• to calculate the proportion of cases exposed to specific risk factors, by type of infection; 
• to study variations over time in the relative and attributable risks associated with specific types of exposure, by type 
of infection; and 
• to develop control strategies based on the identification of risk factors at the local level. 
The general method of SEIEVA is: 
• to interview infected persons using an individual questionnaire (SEIEVA form) which includes information on socio-
demographic and risk factors; questionnaire is administered before results of serological tests are obtained; 
• to provide information on the results of serological tests; 
• to contact the transfusion centre and record information obtained on a specific form if the infected person reports 
that he/she had received a blood transfusion in the six months prior to disease onset; 
• to conduct, when applicable (mainly when outbreaks are identified), case control and cohort studies. 
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Table A3a. Details on case definitions used by the 29 EU/EEA countries in their HBV surveillance 
systems 
Country Classification Content 
Hepatitis B case definition 
Clinical description Laboratory criteria for diagnosis 
Case classification 
Possible Probable Confirmed 
  
  
2002/253/EC: Commission 
Decision of 19 March 2002  
Case definitions for reporting 
communicable diseases to 
the Community network – 
acute hepatitis B 
Viral hepatitis: In symptomatic 
cases, clinical picture 
compatible with hepatitis, e.g. 
discrete onset of symptoms 
and jaundice or elevated 
serum aminotransferase levels. 
IgM antibody to hepatitis 
B core antigen (anti-HBc) 
positive 
 
Detection of HBV nucleic 
acid in serum 
Possible: n/a Probable:  
A case that is 
HBsAg+ and has 
a clinical picture 
compatible with 
acute hepatitis 
Confirmed:  
A case that is 
laboratory 
confirmed 
2008/426/EC: Commission 
Decision of 28 April 2008 
amending Decision 
2002/253/EC  
Case definitions for reporting 
communicable diseases to 
the Community network – 
acute hepatitis B 
Any person with a discrete 
onset of symptoms (e.g. 
fatigue, abdominal pain, loss of 
appetite, intermittent nausea 
and vomiting)  
AND at least one of the 
following three: fever, 
jaundice, elevated serum 
aminotransferase levels 
Hepatitis B virus core IgM 
antigen-specific antibody 
response 
Possible 
case: n/a 
Probable case: 
Any person 
meeting the 
clinical criteria 
and having an 
epidemiological 
link 
Confirmed 
case:  
Any person 
meeting the 
clinical and 
the 
laboratory 
criteria 
                
Austria  2008/426/EC: Commission 
Decision of 28 April 2008 
amending Decision 
2002/253/EC  
Case definitions for reporting 
communicable diseases to 
the Community network – 
acute hepatitis B 
Any person with a discrete 
onset of symptoms (e.g. 
fatigue, abdominal pain, loss of 
appetite, intermittent nausea 
and vomiting)  
AND at least one of the 
following three: fever, 
jaundice, elevated serum 
aminotransferase levels 
Hepatitis B virus core IgM 
antigen-specific antibody 
response 
no definition 
available 
Any person 
meeting the 
clinical criteria 
and having an 
epidemiological 
link 
Any person 
meeting the 
clinical and 
the 
laboratory 
criteria 
Belgium  No official case definition      IgM+ and/or HBe 
antigen 
      
Bulgaria Extended EU case 
definition 
Acute hepatitis B Cases with clinical symptoms 
compatible with hepatitis, e.g. 
gradual development of the 
symptoms and jaundice or 
elevated serum 
aminotransferase levels 
Detection of IgM 
antibodies against 
Hepatitis B virus core 
antigen (anti-HBc IgM +)  
 
Demonstration of HBV 
nucleic acid in the serum  
n/a A case that is 
HBsAg+ and has 
a clinical picture 
compatible with 
an acute hepatitis 
Confirmed 
lab test 
Chronic hepatitis B A case with a clinical 
presentation compatible with 
chronic hepatitis and 
laboratory findings  
Presence of hepatitis B 
virus surface antigen 
(HBsAg) over a period of 
more than 6 months. 
 
Demonstration of HBV 
nucleic acid in the serum 
over a period of more 
than 6 months 
n/a A case clinically 
compatible with 
chronic hepatitis 
A case 
clinically 
compatible 
with chronic 
hepatitis that 
is laboratory 
confirmed 
Cyprus Possibly an EU case 
definition 
Acute hepatitis B     n/a n/a HBsAg+ and 
compatible 
clinical 
presentation 
Denmark Possibly an EU case 
definition 
Acute hepatitis B clinical symptoms HBsAg+ or only specific 
lab test 
n/a n/a  According to 
clinical signs 
and 
laboratory 
confirmation 
Chronic hepatitis B   Confirmed laboratory 
signs for more than 6 
months 
n/a n/a  Confirmed 
lab test 
Estonia 2008/426/EC: Commission 
Decision of 28 April 2008 
amending Decision 
2002/253/EC  
Case definitions for reporting 
communicable diseases to 
the Community network – 
acute hepatitis B 
Any person with a discrete 
onset of symptoms (e.g. 
fatigue, abdominal pain, loss of 
appetite, intermittent nausea 
and vomiting)  
AND at least one of the 
following three: fever, 
jaundice, elevated serum 
aminotransferase levels 
Hepatitis B virus core IgM 
antigen-specific antibody 
response 
Yes, but no 
definition 
available 
Any person 
meeting the 
clinical criteria 
and having an 
epidemiological 
link 
Any person 
meeting the 
clinical and 
the 
laboratory 
criteria 
Finland  Other  Acute hepatitis B   Acute hepatitis B case. 
EITHER 
1. laboratory-reported 
HBV core-antigen IgM 
antibody positive case;  
OR 
2. physician-reported 
case with clinical 
symptoms compatible 
with acute hepatitis or 
fresh HBV infection  
AND (simultaneously) 
laboratory-verified HBV 
surface antigen positivity 
OR simultaneously 
laboratory-verified HBV 
DNA/RNA + 
n/a n/a n/a 
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Country Classification Content 
Hepatitis B case definition 
Clinical description Laboratory criteria for diagnosis 
Case classification 
Possible Probable Confirmed 
Chronic hepatitis B   All reported HBsAg+ 
cases not meeting the 
acute hepatitis case 
definition 
n/a n/a n/a 
France Extended EU case 
definition 
Acute hepatitis B Acute symptomatic  
(Missing definition) 
IgM + OR (if IgM 
unknown) anti-HBc+ and 
HbsAg+ in clinical 
context 
n/a n/a  
Chronic hepatitis B  HBsAg carriage >6 
months 
 n/a n/a n/a 
Germany 2002/253/EC: Commission 
Decision of 19 March 2002 
Case definitions for reporting 
communicable diseases to 
the Community network – 
acute hepatitis B 
Viral hepatitis: In symptomatic 
cases, clinical picture 
compatible with hepatitis, e.g. 
discrete onset of symptoms 
and jaundice or elevated 
serum aminotransferase levels. 
Laboratory case 
definition: At least one of 
the following three 
criteria: detection of 
hepatitis B virus nucleic 
acid in serum (e.g. PCR), 
HBsAg+ (e.g. ELISA) 
confirmed by a different 
HBsAg test (e.g. HBsAG-
NT)  
OR HBsAg+ and anti-
HBc+, IgM anti-HBc+ 
(e.g. ELISA).  
Confirmed: laboratory 
criteria and clinical criteria 
are fulfilled. 
n/a n/a Confirmed 
lab test 
Greece Extended EU case 
definition 
Acute hepatitis B An acute illness with discrete 
onset of symptoms (e.g. 
jaundice) or elevated serum 
aminotransferase level 
IgM anti-HBc+ or HBV 
DNA+ 
n/a Meets clinical 
criteria and 
HBsAg+ 
Meets clinical 
criteria and is 
laboratory 
confirmed 
Asymptomatic hepatitis B   HbsAg+, asymptomatic 
infants <12 m/o: should 
be notified, other 
asymptomatic case, anti-
HBc IgM+ or HbsAg+: 
should not be notified 
      
Hungary Possibly an EU case 
definition 
Acute hepatitis B  Lab confirmation: 
hepatitis B core antigen 
(IgM anti-HBc+) or HBV 
DNA in the blood 
n/a HBsAg-positive 
patient with 
clinical symptoms 
Lab 
confirmed 
Iceland Other  Acute hepatitis B n/a  n/a n/a All newly lab- 
confirmed 
HBV cases 
are 
reportable, 
both acute 
and chronic 
cases, 
regardless of 
symptoms 
Chronic hepatitis B n/a Laboratory-confirmed 
cases with serological 
tests and medical history 
compatible with previous 
HBV infection 
n/a n/a No data 
Ireland Extended EU case 
definition 
Acute hepatitis B Viral hepatitis: In symptomatic 
cases, clinical picture 
compatible with hepatitis, e.g. 
discrete onset of symptoms 
and jaundice or elevated 
serum aminotransferase levels. 
IgM antibody to hepatitis 
B core antigen (IgM anti-
HBc+)  
 
Detection of HBV nucleic 
acid in serum 
n/a Probable: A case 
that is HBsAg+ 
and has a clinical 
picture 
compatible with 
an acute hepatitis 
Confirmed: A 
case that is 
laboratory 
confirmed 
Chronic hepatitis B   HBsAg+ and antibodies 
to hepatitis B, anti-HBc+ 
and IgM to Hbc, 
persistence of more than 
6 months of either HBsAg 
or HBV nucleic acid in 
serum 
n/a n/a Confirmed: 
A case that is 
laboratory 
confirmed 
Italy Possibly an EU case 
definition 
Acute hepatitis B  IgM anti-HBc+ and 
HBsAg+. 
n/a n/a Lab 
confirmed 
Latvia 2008/426/EC: Commission 
Decision of 28 April 2008 
amending Decision 
2002/253/EC  
Case definitions for reporting 
communicable diseases to 
the Community network – 
acute hepatitis B 
Any person with a discrete 
onset of symptoms (e.g. 
fatigue, abdominal pain, loss of 
appetite, intermittent nausea 
and vomiting)  
AND at least one of the 
following three: fever, 
jaundice, elevated serum 
aminotransferase levels 
Hepatitis B virus core IgM 
antigen-specific antibody 
response 
n/a Any person 
meeting the 
clinical criteria 
and having an 
epidemiological 
link 
Any person 
meeting the 
clinical and 
the 
laboratory 
criteria 
Liechtenstein No case definition         
Lithuania 2008/426/EC: Commission 
Decision of 28 April 2008 
amending Decision 
2002/253/EC  
Case definitions for reporting 
communicable diseases to 
the Community network – 
acute hepatitis B 
Any person with a discrete 
onset of symptoms (e.g. 
fatigue, abdominal pain, loss of 
appetite, intermittent nausea 
and vomiting) AND at least 
one of the following three: 
Fever, Jaundice, Elevated 
serum aminotransferase levels 
Hepatitis B virus core IgM 
antigen-specific antibody 
response 
n/a Any person 
meeting the 
clinical criteria 
and having an 
epidemiological 
link 
Any person 
meeting the 
clinical and 
the 
laboratory 
criteria 
Luxembourg No case definition          
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Country Classification Content 
Hepatitis B case definition 
Clinical description Laboratory criteria for diagnosis 
Case classification 
Possible Probable Confirmed 
Malta 2002/253/EC: Commission 
Decision of 19 March 2002 
Case definitions for reporting 
communicable diseases to 
the Community network – 
acute hepatitis B 
Viral hepatitis: In symptomatic 
cases, clinical picture 
compatible with hepatitis, e.g. 
discrete onset of symptoms 
and jaundice or elevated 
serum aminotransferase levels 
IgM anti-HBc+ 
Detection of HBV nucleic 
acid in serum. 
n/a A case that is 
HBsAg+ and has 
a clinical picture 
compatible with 
an acute hepatitis 
A case that is 
laboratory 
confirmed 
Netherlands Extended EU case 
definition 
Acute hepatitis B Any person with a discrete 
onset of symptoms (e.g. 
fatigue, abdominal pain, loss of 
appetite, intermittent nausea 
and vomiting)  
AND at least one of the 
following three: fever, 
jaundice, elevated serum 
aminotransferase levels 
Heaptitis B virus core IgM 
or HBsAg+ 
n/a n/a Any person 
meeting the 
clinical and 
the 
laboratory 
criteria 
Chronic hepatitis B   HBsAg+  n/a n/a Confirmed 
lab test 
Norway Other  Acute hepatitis B Person with clinical acute 
hepatitis (not specified) 
Any person with clinical 
acute hepatitis and 
presence of HbsAg and 
presence of at least one 
of the following 
laboratory criteria:  
HbeAg, HBV-RNA, anti-
Hbc (IgG or IgM)  
OR 
any person with 
confirmed anti-Hbc 
seroconversion during 
the last 12 months  
and the presence of at 
least one of the following 
laboratory criteria:  
HbsAg, HBV-RNA, anti-
HbsAb (with no history of 
previous vaccination) 
n/a n/a Confirmed 
lab test 
Chronic hepatitis B n/a Detection of HBsAg and 
HBcAb over more than 6 
months and no clinical 
picture of acute hepatitis 
n/a n/a Confirmed 
lab test 
Poland 2008/426/EC: Commission 
Decision of 28 April 2008 
amending Decision 
2002/253/EC  
Case definitions for reporting 
communicable diseases to 
the Community network – 
acute hepatitis B 
Viral hepatitis: In symptomatic 
cases, clinical picture 
compatible with hepatitis, e.g. 
discrete onset of symptoms 
and jaundice or elevated 
serum aminotransferase levels 
IgM antibody to hepatitis 
B core antigen (IgM anti-
HBc+) 
Detection of HBV nucleic 
acid in serum 
n/a A case that is 
HBsAg+ and has 
a clinical picture 
compatible with 
an acute hepatitis 
Confirmed 
lab test 
Portugal 2008/426/EC: Commission 
Decision of 28 April 2008 
amending Decision 
2002/253/EC  
Case definitions for reporting 
communicable diseases to 
the Community network – 
acute hepatitis B 
Any person with a discrete 
onset of symptoms (e.g. 
fatigue, abdominal pain, loss of 
appetite, intermittent nausea 
and vomiting)  
AND at least one of the 
following three: fever, 
jaundice, elevated serum 
aminotransferase levels 
Hepatitis B virus core IgM 
antigen-specific antibody 
response 
Yes, but no 
definition 
available 
Person with 
disease 
compatible with 
the case definition 
for clinical HBV, 
epidemiologically 
related to a 
confirmed case 
30 to 180 days 
before onset of 
symptoms 
Any person 
meeting the 
clinical and 
the 
laboratory 
criteria 
Romania 2002/253/EC: Commission 
Decision of 19 March 2002 
Case definitions for reporting 
communicable diseases to 
the Community network – 
acute hepatitis B 
Viral hepatitis: In symptomatic 
cases, clinical picture 
compatible with hepatitis, e.g. 
discrete onset of symptoms 
and jaundice or elevated 
serum aminotransferase levels 
IgM antibody to hepatitis 
B core antigen (IgM anti-
HBc+) 
Detection of HBV nucleic 
acid in serum 
n/a A case that is 
HBsAg+ and has 
a clinical picture 
compatible with 
an acute hepatitis 
Confirmed 
lab test 
Slovakia Possibly an EU case 
definition 
Acute hepatitis B Viral hepatitis: In symptomatic 
cases, clinical picture 
compatible with hepatitis, e.g. 
discrete onset of symptoms 
and jaundice or elevated 
serum aminotransferase levels 
Laboratory confirmed 
(not specified) 
n/a Not specified Any person 
meeting the 
clinical and 
the 
laboratory 
criteria  
Slovenia 2008/426/EC: Commission 
Decision of 28 April 2008 
amending Decision 
2002/253/EC  
Case definitions for reporting 
communicable diseases to 
the Community network – 
acute hepatitis B 
Any person with a discrete 
onset of symptoms (e.g. 
fatigue, abdominal pain, loss of 
appetite, intermittent nausea 
and vomiting)  
AND at least one of the 
following three: fever, 
jaundice, elevated serum 
aminotransferase levels 
Hepatitis B virus core IgM 
antigen-specific antibody 
response 
n/a Any person 
meeting the 
clinical criteria 
and having an 
epidemiological 
link 
Any person 
meeting the 
clinical and 
the 
laboratory 
criteria 
Spain 2008/426/EC: Commission 
Decision of 28 April 2008 
amending Decision 
2002/253/EC  
Case definitions for reporting 
communicable diseases to 
the Community network – 
acute hepatitis B 
Any person with a discrete 
onset of symptoms (e.g. 
fatigue, abdominal pain, loss of 
appetite, intermittent nausea 
and vomiting)  
AND at least one of the 
following three: fever, 
jaundice, elevated serum 
aminotransferase levels 
Hepatitis B virus core IgM 
antigen-specific antibody 
response 
n/a Any person 
meeting the 
clinical criteria 
and having an 
epidemiological 
link 
Any person 
meeting the 
clinical and 
the 
laboratory 
criteria 
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Country Classification Content 
Hepatitis B case definition 
Clinical description Laboratory criteria for diagnosis 
Case classification 
Possible Probable Confirmed 
Sweden Other Acute hepatitis B No data HBsAg+  
OR  
HBV-DNA+ 
AND  
anti-HBc IgM+ 
OR HBV-DNA+ with or 
without detectable HBsAg 
AND not detectable anti-
HBc 
n/a Any case meeting 
the clinical criteria 
and having an 
epidemiological 
link 
Any case 
meeting the 
clinical and 
the 
laboratory 
criteria 
Chronic hepatitis B n/a HBV chronic infection: 
HBsAg+  
AND anti-HBcIgG+ 
AND not detectable or 
low levels of HBV anti-
core IgM (anti-HBc IgM) 
n/a n/a Confirmed 
lab test 
United  
Kingdom 
Other  Acute hepatitis B Not specified HBsAg+ and anti-HBc 
IgM+ 
AND 
abnormal liver function 
tests showing a pattern 
consistent with acute 
viral hepatitis. 
n/a n/a Confirmed 
lab test 
Chronic hepatitis B   Chronic HBV case 
definition 
 
Hepatitis B surface 
antigen (HBsAg+) twice, 
at least 6 months apart 
 
OR 
HBsAg+ and anti-HBc 
IgM2, negative and anti-
HBc+. 
n/a n/a Confirmed 
lab test 
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Table A3b. Details on case definitions used by the 29 EU/EEA countries in their HCV surveillance 
systems 
Country Classification Content 
Hepatitis C case definition 
Clinical description Laboratory criteria for diagnosis Case classification 
  Possible Probable Confirmed 
  2002/253/EC: 
Commission Decision of 
19 March 2002 
Case definitions for 
reporting to the Community 
– hepatitis C 
Viral hepatitis: In 
symptomatic cases, clinical 
picture compatible with 
hepatitis, e.g. discrete onset 
of symptoms and jaundice 
or elevated serum 
aminotransferase levels 
• Detection of HCV-
specific antibodies 
• Detection of HCV 
nucleic acid from 
clinical samples 
Possible: n/a Probable: n/a Confirmed: A 
symptomatic 
case that is 
laboratory 
confirmed 
  2008/426/EC: 
Commission Decision of 
28 April 2008 amending 
Decision 2002/253/EC  
Case definitions for 
reporting to the Community 
– hepatitis C 
Not relevant for surveillance 
purposes 
At least one of the 
following two: Detection 
of hepatitis C virus nucleic 
acid in serum  
OR hepatitis-C-virus- 
specific antibody 
response confirmed by a 
different antibody test 
Possible case: 
n/a 
Probable case: 
n/a 
Confirmed 
case: Any 
person 
meeting the 
laboratory 
criteria 
                
Austria 2008/426/EC: 
Commission Decision of 
28 April 2008 amending 
Decision 2002/253/EC  
Case definitions for 
reporting to the Community 
– hepatitis C 
Not relevant for surveillance 
purposes 
At least one of the 
following two: Detection 
of hepatitis C virus nucleic 
acid in serum  
OR  
hepatitis-C-virus-specific 
antibody response 
confirmed by a different 
antibody test 
Possible case: 
n/a 
Probable case: 
n/a 
Confirmed 
case: Any 
person 
meeting the 
laboratory 
criteria 
Belgium No case definition    PCR +   PCR positive 
patient 
Bulgaria Extended EU case 
definition 
Acute hepatitis C Cases with clinical 
symptoms compatible with 
hepatitis, e.g. gradual 
development of the 
symptoms and jaundice or 
elevated serum 
aminotransferase levels 
Demonstration of HCV-
specific antibodies and 
HCV nucleic acid in 
clinical specimens 
n/a n/a A clinical 
case that is 
laboratory 
confirmed 
Chronic hepatitis C A case with a clinical 
presentation compatible 
with chronic hepatitis and 
laboratory findings 
Demonstration of HCV-
specific antibodies for a 
long period (years) and 
nucleic acid in clinical 
specimens for a long 
period (years) 
n/a n/a A case 
clinically 
compatible 
with chronic 
hepatitis that 
is laboratory 
confirmed 
Cyprus Possibly an EU case 
definition 
Hepatitis C (acute and 
chronic) 
Compatible clinical picture 
(not specified) 
Not specified n/a n/a According to 
clinical signs 
and 
laboratory 
confirmation 
Czech 
Republic 
Other  Hepatitis C (acute and 
chronic) 
Compatible clinical picture 
(not specified) 
Anti-HCV Ab positive n/a n/a According to 
clinical signs 
and 
laboratory 
confirmation 
Denmark Possibly an EU case 
definition 
Acute hepatitis C Clinical signs (not specified) Specific lab test for 
microbiological agent 
n/a n/a According to 
clinical signs 
and 
laboratory 
confirmation 
Chronic hepatitis C n/a Confirmed laboratory 
signs for over 6 months 
n/a n/a Confirmed 
lab test 
Estonia 2002/253/EC: 
Commission Decision of 
19 March 2002 
Case definitions for 
reporting to the Community 
– hepatitis C 
Viral hepatitis: In 
symptomatic cases, clinical 
picture compatible with 
hepatitis, e.g. discrete onset 
of symptoms and jaundice 
or elevated serum 
aminotransferase levels 
Detection of HCV-specific 
antibodies 
 
Detection of HCV nucleic 
acid from clinical samples 
 n/a  n/a Any person 
meeting the 
laboratory 
criteria 
Finland 2008/426/EC: 
Commission Decision of 
28 April 2008 amending 
Decision 2002/253/EC  
Case definitions for 
reporting to the Community 
– hepatitis C 
n/a Anti HCV + 
 
OR  
 
HCV RNA + 
n/a  n/a Any person 
meeting the 
laboratory 
criteria 
France 2008/426/EC: 
Commission Decision of 
28 April 2008 amending 
Decision 2002/253/EC  
Case definitions for 
reporting to the Community 
– hepatitis C 
n/a Anti HCV +  
OR 
HCV RNA + 
OR HCV seroconversion 
n/a  n/a Any person 
meeting the 
laboratory 
criteria 
Germany 2008/426/EC: 
Commission Decision of 
28 April 2008 amending 
Decision 2002/253/EC  
Case definitions for 
reporting to the Community 
– hepatitis C 
Not relevant for surveillance 
purposes 
HCV RNA (e.g. PCR); 
anti-HCV + (e.g. ELISA), 
confirmed by a different 
antibody test (e.g. 
immunoblot).  
n/a  n/a Confirmed 
cases: newly 
laboratory-
confirmed 
hepatitis C, 
regardless 
whether 
acute or 
chronic  
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Country Classification Content 
Hepatitis C case definition 
Clinical description Laboratory criteria for diagnosis Case classification 
  Possible Probable Confirmed 
Greece Extended EU Hepatitis C (acute) An acute illness with discrete 
onset of symptoms (e.g. 
jaundice) or elevated serum 
aminotransferase level 
Anti-HCV +  
AND 
IgM anti-HAV – 
 AND 
anti-HBC IgM – 
 
OR  
HCV RNA + 
n/a n/a According to 
clinical signs 
and 
laboratory 
confirmation 
Hungary Possibly an EU case 
definition 
Acute hepatitis C Clinical signs (not specified) Anti-HCV + 
 OR 
HCV RNA + 
n/a n/a According to 
clinical signs 
and 
laboratory 
confirmation 
Iceland 2008/426/EC: 
Commission Decision of 
28 April 2008 amending 
Decision 2002/253/EC  
Case definitions for 
reporting to the Community 
– hepatitis C 
Not relevant for surveillance 
purposes 
HCV RNA + (in serum) 
OR  
Anti-HCV + (confirmed by 
a different antibody test 
n/a  n/a Any person 
meeting the 
laboratory 
criteria 
Ireland Extended EU Hepatitis C (acute and 
chronic) 
In symptomatic cases, 
clinical picture compatible 
with hepatitis, i.e. discrete 
onset of symptoms and/or 
jaundice or elevated serum 
aminotransferase levels. 
Asymptomatic cases are 
common. 
Anti-HCV + 
OR 
HCV RNA +  
n/a n/a Any person 
meeting the 
laboratory 
criteria 
Italy Possibly an EU case 
definition 
Acute hepatitis C Not relevant for surveillance 
purposes 
Lab confirmation (not 
specified) 
n/a n/a  Any person 
meeting the 
laboratory 
criteria 
Latvia 2008/426/EC: 
Commission Decision of 
28 April 2008 amending 
Decision 2002/253/EC  
Case definitions for 
reporting to the Community 
– hepatitis C 
Not relevant for surveillance 
purposes 
HCV RNA + (e.g. PCR); 
anti-HCV + (e.g. ELISA), 
confirmed by a different 
antibody test  
n/a  n/a Any person 
meeting the 
laboratory 
criteria 
Liechtenstein No information       
Lithuania 2008/426/EC: 
Commission Decision of 
28 April 2008 amending 
Decision 2002/253/EC  
Case definitions for 
reporting to the Community 
– hepatitis C 
Not relevant for surveillance 
purposes 
HCV RNA + (e.g. PCR); 
anti-HCV + (e.g. ELISA), 
confirmed by a different 
antibody test 
n/a  n/a Any person 
meeting the 
laboratory 
criteria 
Luxembourg No case definition     n/a n/a C 
Malta 2002/253/EC: 
Commission Decision of 
19 March 2002 
Case definitions for 
reporting to the Community 
– hepatitis C 
In symptomatic cases, 
clinical picture compatible 
with hepatitis, e.g. discrete 
onset of symptoms and 
jaundice or elevated serum 
aminotransferase levels 
Anti-HCV + 
 OR 
HCV RNA + 
 n/a  n/a Symptomatic 
case that is 
laboratory 
confirmed. 
Netherlands Other  Hepatitis C (Acute) Having symptoms (like 
icterus or increased liver 
function disorder) or 
exposure to relevant risks if 
present in recent period, 
including medical treatment 
Appearance of antibodies 
against HCV or increase 
in laboratory reactivity 
n/a n/a Every new 
diagnosis of 
HCV must be 
notified, 
suspecting a 
recent 
infection 
(previous 
year) 
Norway 2008/426/EC: 
Commission Decision of 
28 April 2008 amending 
Decision 2002/253/EC  
Case definitions for 
reporting to the Community 
– hepatitis C 
Not relevant for surveillance 
purposes 
HCV RNA + (e.g. PCR); 
anti-HCV + (e.g. ELISA), 
confirmed by a different 
antibody test 
n/a  n/a Any person 
meeting the 
laboratory 
criteria 
Poland 2008/426/EC: 
Commission Decision of 
28 April 2008 amending 
Decision 2002/253/EC  
Case definitions for 
reporting to the Community 
– hepatitis C 
In symptomatic cases, 
clinical picture compatible 
with hepatitis, e.g. discrete 
onset of symptoms and 
jaundice or elevated serum 
aminotransferase levels 
HCV RNA + (e.g. PCR); 
anti-HCV + (e.g. ELISA), 
confirmed by a different 
antibody test 
 n/a  n/a Any person 
meeting the 
laboratory 
criteria 
 
Portugal Extended EU Hepatitis C (acute) Acute disease with insidious 
initial symptoms (fever, 
malaise, anorexia, nausea, 
asthenia) and elevation of 
serum transaminases, with 
or without icterus 
Lab confirmation (not 
specified) 
  Case with 
clinical 
symptoms and 
epidemiologica
lly linked to 
confirmed 
cases during 
the incubation 
period 
Symptomatic 
cases with 
laboratory 
confirmation 
Romania 2002/253/EC: 
Commission Decision of 
19 March 2002 
Case definitions for 
reporting to the Community 
– hepatitis C 
In symptomatic cases, 
clinical picture compatible 
with hepatitis, e.g. discrete 
onset of symptoms and 
jaundice or elevated serum 
aminotransferase levels 
Anti-HCV + 
 OR 
HCV RNA + 
 n/a  n/a Symptomatic 
case that is 
laboratory 
confirmed. 
Slovakia Possibly an EU case 
definition 
Hepatitis C (acute and  
chronic) 
Not specified Not specified n/a n/a Symptomatic 
case that is 
laboratory 
confirmed 
Slovenia 2008/426/EC: 
Commission Decision of 
28 April 2008 amending 
Decision 2002/253/EC  
Case definitions for 
reporting to the Community 
– hepatitis C 
Not relevant for surveillance 
purposes 
HCV RNA + (e.g. PCR); 
anti-HCV + (e.g. ELISA), 
confirmed by a different 
antibody test 
n/a  n/a Any person 
meeting the 
laboratory 
criteria 
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Country Classification Content 
Hepatitis C case definition 
Clinical description Laboratory criteria for diagnosis Case classification 
  Possible Probable Confirmed 
Spain 2002/253/EC: 
Commission Decision of 
19 March 2002 
Case definitions for 
reporting to the Community 
– hepatitis C 
An acute illness with a 
discrete onset of any sign or 
symptom consistent with 
acute viral hepatitis (e.g. 
anorexia, abdominal 
discomfort, nausea, 
vomiting and jaundice) and 
increase in transaminase 
(ALT, AST) 
Anti-HCV + 
 OR 
HCV RNA + 
 n/a Not specified Symptomatic 
case that is 
laboratory 
confirmed 
Sweden Other  Case definitions for 
reporting to the Community 
– hepatitis C (Acute) 
Not relevant for surveillance 
purposes 
HCV acute infection: 
seroconversion to anti-
HCV within 6 months 
between samples 
n/a n/a Any person 
with recent 
seroconversion 
Case definitions for 
reporting to the Community 
– hepatitis C (Chronic) 
Not relevant for surveillance 
purposes 
HCV RNA +  
anti-HCV +  
n/a n/a Any person 
meeting the 
laboratory 
criteria 
United 
Kingdom 
Other  Hepatitis C (acute) Not relevant for surveillance 
purposes 
Recent seroconversion 
OR 
HCV RNA +or antigen + 
and anti-HCV - 
or equivocal in immune- 
competent individual  
OR 
anti-HCV + and anti-HAV 
IgM – AND anti-HBc IgM 
– AND abnormal liver 
function tests with a 
pattern consistent with 
acute viral hepatitis in 
someone with recent 
exposure to HCV, e.g. 
needle-stick injury, 
dialysis, recent injecting 
drug use. 
n/a n/a Any person 
meeting the 
laboratory 
criteria 
Hepatitis C (chronic) Not relevant for surveillance 
purposes 
Anti-HCV+ or 
HCV RNA +   
AND not meeting case 
definition for acute HCV 
n/a n/a Any person 
meeting the 
laboratory 
criteria 
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Table A4. Characteristics of HBV/HCV surveillance systems: data sources, type and format of 
database, and frequency of analysis 
  Source of data  Format  Type  Frequency 
Country 
D
is
ea
se
 
P
h
ys
ic
ia
ns
 
La
bo
ra
to
ry
 
H
os
pi
ta
l 
O
th
er
 
Comments  
El
ec
tr
on
ic
 
P
ap
er
 
 
C
as
e 
b
as
ed
 
A
gg
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ga
te
d
 
 
D
ai
ly
 
W
ee
kl
y 
B
iw
ee
kl
y 
M
on
th
ly
 
B
ia
nn
ua
lly
 
Y
ea
rl
y 
Other 
Austria HBV                   
If necessary a 
daily analysis 
is possible. 
 HCV                   
If necessary, a 
daily analysis 
is possible. 
Belgium HBV                    
 HCV                    
Bulgaria HBV                   
Immediately in 
case of 
outbreak 
 HCV                   
Immediately in 
case of 
outbreak 
Cyprus HBV                   Opportunistic 
 HCV                   Opportunistic 
Czech 
Republic HBV 
No 
Information 
provided 
                  
 HCV                    
Denmark HBV                   Ad hoc 
 HCV                   Ad hoc 
Estonia HBV                    
 HCV                    
Finland HBV     *               ** 
 HCV     Blood bank screening              Idem 
France HBV     
Source of data and 
format are related to the 
comprehensive system 
on acute HBV infection 
              
 HCV     National health insurance database              
3 to 10 years, 
depending on 
surveys 
Germany HBV     Physicians and laboratory               
 HCV     Physicians and laboratory               
Greece HBV                    
 HCV                    
Hungary HBV                    
 HCV                    
Iceland HBV                    
 HCV                    
Ireland HBV                   Quarterly 
 HCV                   Quarterly 
Italy HBV                    
 HCV                    
Latvia HBV                Y   As often as necessary 
 HCV     
Laboratories – detection 
of hepatitis C virus 
nucleic acid in serum 
             As often as necessary 
Liechten- 
stein HBV                    
 HCV 
No 
information 
provided 
                  
Lithuania HBV                  Y  
 HCV                  Y  
Luxem- 
bourg HBV                    
 HCV                    
Malta HBV                    
 HCV                    
Nether- 
lands HBV                    
 
 
 
 
TECHNICAL REPORT Surveillance and prevention of hepatitis B and C in Europe 
 
 
 
41 
 
 
 
  Source of data  Format  Type  Frequency 
Country 
D
is
ea
se
 
P
h
ys
ic
ia
ns
 
La
bo
ra
to
ry
 
H
os
pi
ta
l 
O
th
er
 
Comments  
El
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on
ic
 
P
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C
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e 
b
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ly
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y 
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y 
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ly
 
B
ia
nn
ua
lly
 
Y
ea
rl
y 
Other 
 HCV                    
Norway HBV                    
 HCV                    
Poland HBV                    
 HCV                    
Portugal HBV                    
 HCV                   Quarterly  
Romania HBV     Case-based reporting since 2009               
 HCV     Case-based reporting since 2009               
Slovakia HBV                   
Determined by 
professional 
needs, 
regardless of 
time 
 HCV                   Determined by needs 
Slovenia HBV                   
More 
frequently in 
case of 
clusters or 
outbreaks 
 HCV                   
More 
frequently in 
case of 
clusters or 
outbreaks 
Spain HBV                    
 HCV                    
Sweden HBV                    
 HCV                    
United 
Kingdom HBV                   Quarterly 
 HCV                   Quarterly 
 
* There are separate parallel systems for blood bank and maternity screening, although these are covered by the physician and laboratory reporting, too. National personal identifier use 
allows for elimination of duplicate reports 
** Annually produced comprehensive reports. Large healthcare facilities have access to regional data with identifiers, the National Public Health Institute (register maintenance) has 
access to all data with full identifiers.  
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Table A5a. Information collected in HBV surveillance systems in the 29 EU/EEA countries  
 AT BE BG CY DK EE FI FR DE GR HU IS IE IT LV LI LT LU MT NL NO PL PT RO SK SI ES SE UK 
Ba
si
c 
da
ta
 
Patient ID X     X X X X   X X X X X   X X X X X X X X X   X X X X X 
Date of birth or age X X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Gender X X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Country of birth X   X X X   X         X X X   X   X X X X   X     X   X   
Place of residence X X X X X X X X X X X X X X X X X X X X X X X X X X X X   
Date of onset of the disease X   X X X X   X X X X X X X X X X X X X X X X X X X X X   
Date of diagnosis X   X   X X X X X X X X X X X X X   X X X       X     X X 
Date of reporting/notification X X X X X X X X X X X X X X X   X X X X X X X X X X   X X 
Date used for statistics X X X X X X X   X X   X     X     X X X X X     X   X X X 
Country where infection 
most likely acquired X     X X X X X   X X X X   X X X X X X X       X     X   
Immunisation status X   X X X X   X X X X X X X X X X X X X X X X X X X       
Outcome X   X X   X   X   X X   X   X X X   X   X X X X X X X     
Cl
as
si
fic
at
io
n 
in
fo
rm
at
io
n Clinical symptoms X   X   X     X X X X X   X X X     X   X X X   X         
Laboratory results X X X   X X X X X X X X X X X   X   X X X X X X X     X X 
Epidemiological information X   X X X X     X X X X X X X X X   X X X X X X X       X 
Tr
an
sm
is
si
on
 r
ou
te
 r
is
k 
fa
ct
or
s 
Homosexual contact     X   X X   X X     X X X X X X   X X         X     X X 
Heterosexual contact     X   X X   X X     X X X X X X   X X         X     X X 
Injecting drug use     X   X X X X X   X X X X X X X   X X X X   X X     X X 
Mother HBsAg+     X   X X X X X X X X X X X   X   X   X     X X     X X 
Close family member 
HBsAg+     X   X X   X X X X X X X X X X   X   X X   X X       X 
Sex partner HBsAg+     X   X X   X X X X X X X X   X   X   X     X X       X 
Blood or blood product 
transfusion      X   X X X X X X X X X X X X X   X   X X   X X     X X 
Invasive healthcare 
procedure/dental treatment     X   X X   X X X X X X X X   X   X   X     X X     X X 
Organ transplantation     X   X X   X X   X X   X X   X   X   X     X X       X 
Haemodialysis     X   X X   X X X X X X X X X X   X   X     X X       X 
Needle injury or other 
occupational exposure     X   X X   X X X X X X X X   X   X X X       X     X X 
Tattooing/body piercing     X   X X   X X X X X X X X   X   X   X     X X     X X 
Other         X   X   X X   X X   X   X     X                   
O
th
er
 
Hospitalisation X   X X   X   X X   X   X X X X X   X X X X X X X       X 
Length of hospitalisation                 X X X       X       X     X   X X         
ICD code diagnosis       X   X X         X     X   X         X X   X         
Genotype information                         X                                 
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Table A5b. Information collected in HCV surveillance systems in the 29 EU/EEA countries 
 AT BE BG CY CZ DK EE FI FR DE GR HU IS IE IT LV LT LU MT NL NO PL PT RO SK SI ES SE UK 
Ba
si
c 
da
ta
 a
 
Patient ID X     X X X X X   X X X X X   X X X X X X X     X X   X X 
Date of birth or age X X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Gender X X X X X X X X X X X X X X X X X X X X X X X X X X X X X 
Country of birth X   X X   X   X X       X X X     X X X X   X         X   
Place of residence X X X X X X X X X X X X X X X X X X X X X X X X X X X X   
Date of onset of the disease X   X X   X X X X X X X X   X X X X X X X X X   X X   X   
Date of diagnosis X   X     X X X X X X X X X X X X   X X X       X   X X X 
Date of reporting/notification X X X X X X X X X X X X X X X X X X X X X X X X X X   X X 
Date used for statistics X X X X   X X X   X X   X     X   X X   X X     X     X X 
Country where infection 
most likely acquired X     X X X X X     X X X X   X X X X X X       X     X X 
Immunisation status X     X     X   X   X       X X   X X     X X             
Outcome X   X X     X       X X       X X   X   X   X X X   X     
Cl
as
si
fic
at
io
n 
in
fo
rm
at
io
n Clinical symptoms X   X     X       X X X X   X X     X   X X     X       X 
Laboratory results X X X   X X X X X X X X X X X X X   X X X X X X X     X X 
Epidemiological information X   X   X X X   X X X X X X X X X   X X X X X X X       X 
Tr
an
sm
is
si
on
 r
ou
te
 r
is
k 
fa
ct
or
s 
Homosexual contact     X     X X   X X     X   X X X   X X         X     X X 
Heterosexual contact     X     X X     X     X   X X X   X X         X     X X 
Injecting drug use     X   X X X X X X   X X X X X X   X X X X   X X     X X 
Mother HCV +     X     X X     X X   X X X X X   X   X       X     X X 
Close family member HCV +     X     X X     X X X X   X X X   X   X X   X X       X 
Sex partner HCV positive     X     X X     X X X X X X X X   X   X     X X     X X 
Blood or blood product 
transfusion      X   X X X X X X X X X X X X X   X   X X   X X     X X 
Invasive healthcare 
procedure/dental treatment     X   X X X   X X X X X X X X X   X   X X   X X     X X 
Organ transplantation     X   X X X     X   X X X X X X   X   X     X X       X 
Haemodialysis     X   X X X   X X X X X X X X X   X   X     X X       X 
Needle injury or other 
occupational exposure     X   X X X   X X X X X X X X X   X X X       X     X X 
Tattooing/body piercing     X   X X X   X X X X X X X X X   X   X     X X     X X 
Other           X       X X   X X     X     X         X         
O
th
er
 
Hospitalisation X   X X X   X     X   X     X X X   X X X X X X X       X 
Length of hospitalisation                   X X X       X     X     X   X X         
ICD code diagnosis       X X   X X         X     X X         X X   X         
Genotype information                 X         X     X                         
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Table A6a. Screening programmes for hepatitis B in 29 EU/EEA countries 
 AT BE BG CY DK EE FI FR DE GR HU IS IE IT LV LI LT LU MT NL NO PL PT RO SK SI ES SE UK 
Pregnant women X     X X X X X X X X X X X X X     X X X X X   X X X X X 
Military recruits                                     X       X   X         
Injecting drug users     X X X       X X X X X           X   X   X X X X   X   
STI clinic patients       X       X X X     X           X       X X X         
Multiple sex partners                 X                                        
Prisoners       X   X   X X       X           X   X   X   X X   X   
Haemodialysis patients   X X X       X X X X X X X X       X   X X X   X X X X X 
Long-term healthcare 
facilities       X                 X                                 
Healthcare workers   X           X X       X X         X         X           
Workers who are 
occupationally  
exposed to the virus 
              X X   X     X X   X   X     X X       X   X 
Blood and organ donors X X X X X X X X X X X   X X X   X   X X X X X X X X X X X 
Comments: 
• Austria: Several scientific projects on HBV-screening, but no national prevention programmes;  
• France: Anonymous testing centres for HBV and HCV;  
• Germany: For example, HIV-positives which attended an STI clinic;  
• Ireland: screening of healthcare workers for hepatitis B applies only to healthcare workers involved in exposure-prone 
procedures; screening for persons with multiple sex partners would only take place if the person attended an STI clinic;  
• Latvia: ‘Expanding Network for Comprehensive and Coordinated Action on HIV/AIDS Prevention Among IDUs and Bridging 
Population’, ENCAP No. 2005305 ‘Prevalence of HIV and other infections; risk behaviour among injecting drug users and 
bridging populations in Latvia, Lithuania, Estonia’.  Anti-HBc prevalence among IDUs in Latvia: 55.8% (2007);  
• Netherlands: behavioural high risk groups for HBV are screened when receiving the first vaccination;  
• Slovenia. Screening of prisoners. Most screenings are conducted for risk groups. Slovenia does not have a mandatory 
military service, the Slovenian armed forces are professional soldiers who are vaccinated against many communicable 
diseases. They are vaccinated against HBV according to risk assessments connected to their working places and the 
standards of peacekeeping missions;  
• Sweden. No complete mandatory screening, except for blood and organ donors. Other groups are offered tests, but extent 
differs in different counties. 
 
Table A6b. Screening programmes for hepatitis C in 29 EU/EEA countries 
 AT BE BG CY CZ DK EE FI FR DE GR HU IS IE IT LV LT LU MT NL 
N
O PL PT RO SK SI ES SE UK 
Pregnant women                   X  X      X   
Military recruits                         X     
Injecting drug users   X X  X   X X X X X X     X  X  X X X X  X  
STI clinic patients    X      X         X     X X  X   
Multiple sex partners          X                    
Prisoners    X     X X    X     X  X X X  X X  X  
Haemodialysis patients  X X X X   X X X X  X X X X   X  X X X  X  X X X 
Long-term healthcare 
facilities                              
Healthcare workers  X       X X    X X    X        X  X 
Persons occupationally 
exposed to the virus         X X  X   X X X  X   X       X 
Blood and organ donors X X X X X X X X X X X X X X X X X  X X X X X X X  X X X 
Comments: 
• France: Anonymous testing centres for HBV and HCV  
• Ireland: Since July 2008, all new healthcare workers who are involved in exposure-prone procedures are offered screening 
for HCV 
• Latvia: ‘Expanding Network for Comprehensive and Coordinated Action on HIV/AIDS Prevention among IDUs and Bridging 
Population’, ENCAP No. 2005305. ‘Prevalence of HIV and other infections; risk behaviour among injecting drug users and 
bridging population in Latvia, Lithuania, Estonia’. Anti-HCV positive prevalence among IDUs in Latvia (2007): 74.2%. 
• Slovenia: Prisoners are screened if they are injecting drug users or otherwise suspected of being infected.  
• Sweden: No complete mandatory screening, except for blood and organ donors. Other groups are offered tests, but extent 
differs in different counties. 
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Annex 2. Country overview on HBV and HCV 
surveillance and prevention 
The following tables provide a comprehensive overview of HBV and HCV surveillance and prevention in EU/EEA 
countries. 
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Austria 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Every physician has to report suspected and confirmed cases 
and deaths. Laboratories are included in the Mandatory 
reporting system. 
Every physician has to report suspected and 
confirmed cases and deaths. Laboratories are 
included in the Mandatory reporting system. 
Surveillance system Other, see below: Other, see below: 
Comments Laboratory-confirmed cases Laboratory-confirmed cases 
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical EU case definition 2008 EU case definition 2008 
Chronic EU case definition 2008  EU case definition 2008 
Other   
Cases included in surveillance  Possible   Possible 
 
 
 Probable 
with classification 
Probable 
with classification 
Confirmed Confirmed 
Unknown classification  Unknown classification  
Type of cases Acute Since 1 January 2009 it is 
possible to distinguish between 
acute and chronic. 
Acute Since 1 January 2009 it is 
possible to distinguish 
between acute and 
chronic. 
 Chronic Chronic 
Asymptomatic Asymptomatic 
Suspected  Suspected  
Other: Austria has an electronic 
reporting system with many 
relevant variables which can be 
analysed ad hoc if necessary. 
Other: Austria has an electronic 
reporting system with 
many relevant variables 
which can be analysed ad 
hoc if necessary. 
Including duplicates No No 
Underreporting  Underreporting is possible, but no estimates exist for magnitude 
of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification  Clinical symptoms Classification  Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Trans- 
mission route  
risk factors 
Homosexual contact Trans- 
mission route 
risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational exposure Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
  
Data linked to  Liver transplant Liver cancer Liver transplant Liver cancer 
 Hospital register Mortality Hospital register Mortality 
Other:  It is currently not allowed to link personal data across 
different registers, e.g. through social security number, 
unless there are scientific reasons. There are plans for 
cross-linking data through ELGA, the Electronic Patient 
Report.  
Other: 
Note: It is currently not allowed to link 
personal data across different registers, unless 
there are scientific reasons. See note in HBV. 
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other: If necessary, daily analysis is possible Other: If necessary, daily analysis is 
possible 
Other 
surveillance 
systems 
STI clinic  
surveillance 
Laboratory network Supplementary 
sentinel 
surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel 
surveillance 
Regular sero-surveys in general population Other Regular sero-surveys in general 
population 
Other 
Network of hepatologists (hospital and patient data)  
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women   
Military recruits   
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**    
Vaccination 
programme 
(only HBV) 
HBV  
Universal vaccination Infants 
Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg + mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other:  
Catch-up 
programme 
Infants up to 6 years: three doses 
Adolescents from 7 to 18 years: three doses 
Vaccination 
coverage 
 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: 
Immunisation coverage (infants): under 1 year: 30%; 1 year: 83%; 2 years: 80% 
Immunisation coverage (adolescents): under 11 years: 31%; 11 years: 24%; 12 years: 24%; 13 years: 33%; 14 years: 43% 
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Belgium 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Several surveillance systems for HBV, none of which can be 
characterised as the major one, please describe below 
Several surveillance systems for HCV, none of which 
can be characterised as the major one, please 
describe below 
Surveillance system Other, see below: Other, see below: 
Comments Mandatory notification; 
sentinel laboratory 
Mandatory notification; 
sentinel laboratory 
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical IgM+ and/or HBe antigen PCR+ 
Chronic No case definition  No case definition 
Other   
Cases included in surveillance  Possible 
with classification 
Possible 
with classification  Probable Probable 
Confirmed Confirmed 
Unknown classification  Unknown classification  
     
Type of cases Acute 
with classification 
Acute 
with classification  Chronic Chronic 
Asymptomatic Asymptomatic 
Suspected  Suspected  
Other:  Other:  
Including duplicates Yes yes 
Underreporting  Underreporting is possible, but no estimates exist for magnitude 
of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification  Clinical symptoms Classifi- 
cation 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Trans- 
mission route risk 
factors 
Homosexual contact Transmission 
route risk 
factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational exposure Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
  
Data linked to  Liver transplant Liver cancer  Liver transplant Liver cancer 
 Hospital register Mortality Hospital register Mortality 
 Other: Data linking could be done in theory, but 
never actually carried out 
 Other: Data linking possible, but was never 
actually carried out 
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other: If necessary, daily analysis is possible Other: If necessary, daily analysis is 
possible 
Other 
surveillance 
systems 
STI clinic  
surveillance 
Laboratory network Supplementary 
sentinel 
surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel 
surveillance 
Regular sero-surveys in general population Other Regular sero-surveys in general 
population 
Other 
Sero-prevalence study in 1993, 2003. May be repeated in 2011 Sero-prevalence study in 1993, 2003. May be 
repeated in 2011 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women   
Military recruits    
Injecting drug users   
STI clinic patients    
Multiple sex partners    
Prisoners    
Haemodialysis patients   
Long-term healthcare facilities    
Healthcare workers   
Workers who are occupationally exposed to the virus     
Blood and organ donors   
Other groups**     
Vaccination 
programme 
(only HBV) 
HBV  
Universal vaccination Infants 
Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other: Haemophiliac patients, thalassaemia, organ transplant, patients who will receive 
massive transfusion, mentally disabled people, travellers to HBV endemic area 
Catch-up 
programme 
Infants up to 6 years: three doses 
Adolescents from 7 to 18 years: three doses 
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: 
98% 
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Bulgaria 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system Own system for HBV Own system for HCV 
Comments   
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical Clinical description: 
• Cases with clinical symptoms compatible with hepatitis, 
e.g. gradual development of the symptoms and 
jaundice or elevated serum aminotransferase levels 
Laboratory criteria for diagnosis: 
• Detection of IgM antibodies against Hepatitis B virus 
core antigen (anti-HBc IgM positive) 
• Demonstration of HBV nucleic acid in the serum  
Case classification: 
• Possible: n/a 
• Probable: A case that is HBsAg+ and a clinical picture 
compatible with acute hepatitis.  
• Confirmed: A case that is laboratory confirmed. 
Clinical description: 
• Cases with clinical symptoms compatible with hepatitis, 
e.g. gradual development of the symptoms and 
jaundice or elevated serum aminotransferase levels 
Laboratory criteria for diagnosis: 
• Demonstration of HCV specific antibodies 
• Demonstration of HCV nucleic acid in clinical 
specimens 
Case classification: 
• Possible: n/a 
• Probable: n/a 
• Confirmed: A clinical case that is laboratory-confirmed. 
Chronic Clinical description: 
• A case with a clinical presentation compatible with 
chronic hepatitis and laboratory findings  
• Hepatitis B, chronic 
Laboratory criteria for diagnosis: 
• Presence of hepatitis B virus surface antigen (HBsAg) 
over a period longer than six months 
• Demonstration of HBV nucleic acid in the serum over a 
period longer than six months 
Case classification:  
• Possible: N/A 
• Probable: A case clinically compatible with chronic 
hepatitis  
• Confirmed: A case clinically compatible with chronic 
hepatitis that is laboratory confirmed 
 Clinical description: 
• A case with a clinical presentation compatible with 
chronic hepatitis and laboratory findings 
Laboratory criteria for diagnosis: 
• Demonstration of HCV-specific antibodies over a long 
period (years) 
• Demonstration of nucleic acid in clinical specimens 
over a long period (years) 
Case classification: 
• Possible: N/A 
• Probable: N/A 
• Confirmed: A case clinically compatible with chronic 
hepatitis that is laboratory-confirmed 
Cases included in surveillance  Possible  Possible  
 
 Probable  
with classification 
Probable 
with classification 
Confirmed Confirmed 
Unknown classification  Unknown classification  
Type of cases Acute  
with classification 
Acute  
with classification 
 Chronic  Chronic  
Asymptomatic  Asymptomatic  
Suspected  Suspected  
Other:  Other:  
Including duplicates No No 
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission route risk 
factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational exposure Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
Information is available only at regional level, not at central level. 
Laboratory results: 
anti-HBc IgM ; anti-HBc IgG ; anti-HBe  ; HBe Ag ; anti-HBs; HBsAg 
Information is available only at regional level and is not 
reported at central level. 
Laboratory results: anti-HCV; HCV RNA in some cases 
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other: Immediately in case of outbreak Other: Immediately in case of outbreak 
Other 
surveillance 
systems 
STI clinic surveillance Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general population Other Regular sero-surveys in general 
population 
Other 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women   
Military recruits   
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**   
Vaccination 
programme 
(only HBV) 
HBV  
Universal vaccination Infants 
Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other: HIV infected, persons travelling to countries with high HBV incidence 
Catch-up 
programme 
–  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: 
Universal newborn immunisation:  
2001: 93,33; 2002: 88.28; 2003: 95.85; 2004: 93.8; 2005: 96.0; 2006: 95.9; 2007: 95.4; 2008: 95.7; 2009: 95.6 
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Cyprus 
 HBV  HCV 
Surveillance system 
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system Other, see below: Other, see below: 
Comments 57 communicable diseases are notifiable to the Director of 
Medical and Public Health Services (MPHS) by all practising 
medical doctors (Quarantine Law and its amendments).  
Reporting is done by completion of a specific form which is 
submitted to the District Medical Officer who forwards it to 
the Unit for Surveillance and Control of Communicable 
Diseases (MPHS Central Offices).  
Data are entered in a database (EPI-INFO) and analysed. 
See comment to the left. 
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical Probable: n/a 
 
Possible: HBsAg+ and compatible clinical presentation 
 
Confirmed: Laboratory confirmation and compatible clinical 
picture 
Probable and possible: n/a 
 
Confirmed: Clinically compatible case that is laboratory-
confirmed 
Chronic No case definition  No case definition 
Other   
Cases included in surveillance  Possible  
 
Possible  
 
 Probable Probable 
Confirmed with classification Confirmed with classification 
Unknown classification  Unknown classification  
Type of cases Acute  
with classification 
Acute  
with classification 
 Chronic Chronic 
Asymptomatic Asymptomatic 
Suspected  Suspected  
Other:  Other:  
Including duplicates No No 
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
1. TRRF are covered by an opened-ended question: Risk 
factors/risk predisposition.  2. ICD-10 coding is used 
1. TRRF are covered by an opened-ended question: Risk 
factors/risk predisposition  2. ICD-10 coding is used 
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other: Opportunistic Other: Opportunistic 
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women   
Military recruits   
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**    
Vaccination 
programme 
(only HBV) 
HBV  
Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg mothers 
 Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other:  
Catch-up 
programme 
–  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: 
17–24 years of age: 12% 
2006:  HBV1, 98.6%  ; HBV2, 97.8%; HBV3, 93.2% 
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Czech Republic 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
 Mandatory 
Type of surveillance  Physicians report to primary health care 
Surveillance system  Own system for HCV 
Comments   
 
Objectives 
   HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other  no 
 
Case definition 
Definition    HCV 
Clinical  According to the clinical signs and laboratory confirmation, 
based on anti-HCV Ab 
Chronic   No case definition 
Other   
Cases included in surveillance 
(highlighted in green) 
  Possible  
with classification 
  Probable 
  Confirmed  
  Unknown classification  
Type of cases   Acute  
with classification 
  Chronic 
 Asymptomatic 
  Suspected  
  Other:  
Including duplicates  Yes 
Underreporting   Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
  
 
 
 
 
TECHNICAL REPORT Surveillance and prevention of hepatitis B and C in Europe 
 
 
 
59 
 
 
 
Data 
   HCV 
Source of data    Physicians Laboratory Hospital 
   Other:  
Collected data   Basic data Patient ID 
  Date of birth or age 
 Gender 
 Country of birth 
 Place of residence 
 Date of onset of the disease 
 Date of diagnosis 
 Date of reporting/notification 
 Date used for statistics 
 Country where infection was acquired 
 Immunisation status 
 Outcome 
   Classification 
information 
Clinical symptoms 
 Laboratory results 
 Epidemiological information 
  Transmission 
route risk factors 
Homosexual contact 
 Heterosexual contact 
 Injecting drug use 
 Mother HCV positive 
 Close family member HCV- positive 
 Sex partner HCV positive 
 Blood or blood-product transfusion 
 Invasive healthcare procedure/dental 
treatment 
 Organ transplantation 
 Haemodialysis 
 Needle injury or other occupational 
exposure 
 Tattooing/body piercing 
 Other 
  Other Hospitalisation 
 Length of hospitalisation 
 ICD code diagnosis 
 Genotype information 
  
Data linked to     Liver transplant Liver cancer Mortality 
    Hospital register   
  Other:  
format   Electronic Paper 
Type    Case-based Aggregated Other: 
   
Frequency    Daily Weekly Biweekly 
    Monthly Biannually Yearly 
  Other: Immediately in case of outbreak 
Other surveillance 
systems 
   STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
  Regular sero-surveys in general 
population 
Other 
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Prevention 
   
 
HCV 
Screening 
programme 
Pregnant women   
Military recruits   
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**    
Vaccination 
programme 
(only HBV) 
No information received 
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Denmark 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system Own system for HBV Own system for HCV 
Comments   
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks no no 
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical Clinical symptoms AND (HBsAg+ OR any other specific lab 
test for microbiological agent) 
Clinical symptoms AND specific lab test for microbiological 
agent 
Chronic Confirmed laboratory markers that has existed for more 
than six months 
 Confirmed laboratory markers that has existed for more 
than six months 
Other   
Cases included in surveillance  Possible  
with classification 
Possible  
with classification 
 Probable Probable 
Confirmed  Confirmed  
Unknown classification  Unknown classification  
Type of cases Acute  
with classification 
Acute  
with classification 
 Chronic Chronic 
Asymptomatic  Asymptomatic  
Suspected  Suspected  
Other: Acute hepatitis data 
collected since 1970s; chronic 
hepatitis data since 2000s 
 Other: Acute hepatitis data 
collected since 1970s; chronic 
hepatitis data since 2000s 
 
Including duplicates No No 
Underreporting  Underreporting is possible; please give the rate for 
underreporting (number of reported cases/estimated 
number of real cases) below. 
Underreporting is possible; please give the rate for 
underreporting (number of reported cases/estimated 
number of real cases) below. 
Rate underreporting 50% 50% 
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission route 
risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational exposure Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
Epidemiological link  
 
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other: Difficult and not carried out on a regular 
basis 
Other: Difficult and not carried out on a 
regular basis 
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other: Ad hoc Other: Ad hoc 
Other 
surveillance 
systems 
STI clinic surveillance Laboratory network Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general population Other Regular sero-surveys in general 
population 
Other 
General screening of pregnant women.  
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women    
Military recruits     
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**      
Vaccination 
programme 
(only HBV) 
HBV  
Universal vaccination Infants 
Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other: MSM in Copenhagen municipality 
Catch-up 
programme 
–  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: 
 
 
  
 
 
 
 
Surveillance and prevention of hepatitis B and C in Europe  TECHNICAL REPORT 
 
 
 
64 
 
 
 
Estonia 
 HBV  HCV 
Surveillance system 
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system Other, see below: Other, see below: 
Comments HBV is notifiable disease. Information is provided by GPs, 
hospitals and microbiological labs. Surveillance of HBV is 
part of the national surveillance system. 
HCV is notifiable disease. Information is provided by GPs, 
hospitals and microbiological labs. Surveillance of HCV is 
part of the national surveillance system. 
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical EU 2008 case definition. 
Confirmed case: Any person who meets clinical and 
laboratory criteria. 
Laboratory criteria:  Hepatitis B virus core IgM antigen-
specific antibody response or HBsAg+ or Hepatitis B virus 
NA in serum. 
EU 2008 case definition (as of 1 January 2009) 
Chronic Confirmed case: a case that meets either laboratory criteria 
for diagnosis and does not meet the case definition for 
acute hepatitis B.  Laboratory criteria: IgM antibodies to 
hepatitis B core antigen (anti-HBc) negative and a positive 
result on one of the following tests: hepatitis B surface 
antigen (HBsAg), hepatitis B e-antigen (HBeAg), hepatitis B 
virus (HBV) DNA or HBsAg+ or HBV DNA positive or HBeAg 
positive two times at least six months apart. 
 No case definition 
Other   
Cases included in surveillance  Possible  
with classification 
Possible  
with classification 
 Probable Probable 
Confirmed  Confirmed  
Unknown classification  Unknown classification  
Type of cases Acute  
with classification 
Acute  
with classification 
 Chronic  Chronic  
Asymptomatic  Asymptomatic  
Suspected  Suspected  
Other:  Other:  
Including duplicates No No 
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
  
 
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other:  Other:  
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
 0 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women   
Military recruits   
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**    
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg+ mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other:  
Catch-up 
programme 
–  
Vaccination 
coverage 
Infants 0 to 2 years 
 Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage (2007, estimated): Infants, 2 years of age: 95.8%; Adolescents, 14 years of age: 95.1% 
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Finland 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system Own system for HBV Several surveillance systems for HCV, one of which is the 
major and most comprehensive one. 
Comments Part of the general surveillance system for Infectious 
diseases; one of the infections screened from expecting 
mothers. 
The main system is the National Infectious Disease 
Register, which is the mandatory system for notifiable 
diseases. 
The secondary system is a sampling-based anonymous 
prevalence estimation system for injecting drug users 
which serves as a sentinel surveillance system. This is 
performed every one to two years. 
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other To prevent mother-to-child transmission through pregnant 
women screening 
no 
 
Case definition 
Definition  HBV  HCV 
Clinical No case definition No case definition 
Chronic All reported HBV surface antigen-positive cases not fulfilling 
the acute hepatitis B infection case definition 
 No case definition 
Other Acute hepatitis B case. 
 1. Laboratory reported HBV core-antigen IgM antibody 
positive case; OR 
2. Physician reported case with clinical symptoms 
compatible with acute hepatitis or fresh HBV infection 
AND (simultaneous laboratory verified HBV surface antigen 
positivity OR simultaneous laboratory verified HBV 
DNA/RNA positivity) 
HCV case: 
Anti-HCV antibody positivity 
OR 
HCV RNA positivity 
Cases included in surveillance  Possible  
with classification 
Possible  
with classification 
 Probable Probable 
Confirmed  Confirmed  
Unknown classification  Unknown classification  
Type of cases Acute  
with classification 
Acute with classification 
 Chronic  Chronic  
Asymptomatic  Asymptomatic  
Suspected  Suspected  
Other:  Other: Only included HCV case: 
Anti-HCV + OR 
HCV RNA + 
Including duplicates No No 
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other: Separate parallel system for blood bank 
and maternity screening covered by the 
physician and laboratory reporting. 
National personal identifier allows for 
elimination of duplicate reports. 
Other: Blood bank screening 
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
Nationality is collected as basic data 
Classification: HBV anti-core IgM antibody status (+/-/not 
done), HBV surface antigen status (+/-/not done), HBV 
DNA/RNA status (+/-/not done), histology as part of 
clinical diagnosis (positive/empty) 
Transmission risk factors: sexual contact (to be split in 
homosexual/heterosexual in 2009); Perinatal transmission; 
open ended 
Other: ICD-10 
Nationality is collected as basic data 
Classification:anti-HCV antibody status (+/-/not done), 
HCV DNA/RNA status (+/-/not done), histology as part of 
clinical diagnosis(positive/empty) 
Transmission risk factors: sexual contact (to be split in 
Homosexual/Heterosexual in 2009); Perinatal transmission; 
open ended 
Other: ICD-10 
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
  Cross-sectional cohort prevalence data 
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
 
 
 
 
TECHNICAL REPORT Surveillance and prevention of hepatitis B and C in Europe 
 
 
 
69 
 
 
 
Other: Annually comprehensive reports include 
a review of the situation; all data is 
online (without identifiers). Large 
healthcare facilities have access to 
regional data with identifiers; the 
National Public Health Institute (register 
maintenance) has access to all data 
with full identifiers. 
Other: Annually comprehensive reports 
include a review of the situation; data 
is online (without identifiers). Large 
healthcare facilities have access to 
regional data with identifiers; the 
National Public Health Institute 
(register maintenance) has access to 
all data with full identifiers. 
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
Very active test-offering (but participation voluntary) at 
needle-exchange sites, prisons and addiction treatment 
centres. The two former are actively monitored. 
Sampling-based anonymous prevalence estimation system 
for injecting drug users which serves as a sentinel 
surveillance system (every one to two years). 
 
 
Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women    
Military recruits     
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**      
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg + mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other: 1. Blood clotting disorder patients requiring regular blood product treatment 
2. Household contacts of injecting drug users 
3. Healthcare trainees practicing in a country with high HBV prevalence 
4. Sex workers 
5. Sex partners of acute and chronic carrier cases 
Catch-up 
programme 
Injecting drug users, continuous activity at needle exchange and low-threshold health service sites. 
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
 Other groups 
 Coverage Not known 
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France 
 HBV  HCV 
Surveillance system 
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Voluntary 
Type of surveillance Passive Depends on surveys 
Surveillance system Several surveillance systems for HBV, one of which is the 
major and most comprehensive one. 
Several surveillance systems for HCV, one of which is the 
major and most comprehensive one. 
Comments Mandatory reporting of acute hepatitis B (main system) 
 
Chronic cases: seroprevalence surveys, lab and reference 
sentinel systems, blood donor surveillance 
Lab activity for HCV screening; HCV prevalence surveys 
(drug users, HIV+, MSM, general population); HCV 
seroconversion surveys: blood donors, occupationally 
acquired infections in HCW, accidental exposures in HC 
settings; Newly referred HCV+ patients in hepatology 
centres 
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks no no 
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical Acute symptomatic hepatitis B defined as a patient with 
positive IgM antibodies, or (if IgM unknown) positive anti-
HBc and HbsAg in clinical context of hepatitis 
No case definition 
Chronic HBsAg carriage > 6 months  No case definition 
Other  Confirmed cases: 
anti-HCV positivity, HCV RNA positivity; 
anti-HCV seroconversion 
Cases included in surveillance  Possible  
with classification 
Possible  
with classification 
 Probable Probable 
Confirmed  Confirmed  
Unknown classification  Unknown classification  
Type of cases Acute with classification Acute with classification 
 Chronic Chronic 
Asymptomatic Asymptomatic 
Suspected  Suspected  
Other:  Other: Classification: depends on 
survey 
   
Including duplicates No Yes 
   
Underreporting  Underreporting is possible; see below for rate of 
underreporting (number of reported cases/estimated 
number of actual cases) 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting 23.4%  
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
Jaundice only; lab: qualitative results (HbsAg, anti-HBc 
antibodies (IgM and total) Quantitative results: ALAT 
Data collection depends on surveys: HIV and HBV co-
infections; Socio-economic data, level of education, etc. 
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other:  Other: 3-10 years depending on surveys 
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
For chronic cases only: Network of hepatology reference 
centres; laboratory network; 10-year intervals between 
surveys 
Sero surveys (drug users, HIV+, MSM, general population) 
every 6 to 10 years; HCV seroconversion surveys: blood 
donors, occupationally acquired infections in HCW, 
accidental exposures in HC settings;  Newly referred HCV+ 
patients in hepatology centres, 2001–07 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women    
Military recruits    
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**    Acute confirmed cases of hepatitis C in 
France: implemented in 2006 and 2007 
only, targeted a specific population (HIV-
infected men who have sex with men) 
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg+ mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other: Prisoners; residents in psychiatric institution; travellers to high-endemic countries 
Catch-up 
programme 
  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
 Adults 
 Other groups 
 Not known 
 Coverage: 
0-2-year-olds: 35% 
10-year-olds: 39% 
15-year-olds: 42% 
Adults: 32% 
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Germany 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system Own system for HBV Own  system for HCV 
Comments   
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in 
disease distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical At least one of the following three criteria: jaundice, 
elevated serum aminotransferase levels, abdominal pain. A 
known chronic infection is excluded. 
At least one of the following three criteria: jaundice, 
elevated serum aminotransferase levels, abdominal pain. 
Chronic   Same as above. 
Other Laboratory case definition: At least one of the following 
three criteria: detection of hepatitis B virus nucleid acid in 
serum (e.g. PCR); HBsAg positive (e.g. ELISA), confirmed 
by a different HBsAg test (e.g. HBsAG-NT); OR 
HBsAg positive and anti-HBc positive, anti-HBC-IgM 
positive (e.g. ELISA). 
Confirmed: laboratory criteria and clinical criteria are 
fulfilled. 
Laboratory case definition: At least one of the following 
two criteria: detection of hepatitis C virus nucleic acid in 
serum (e.g. PCR); hepatitis C virus-specific antibody 
response (e.g. ELISA), confirmed by a different antibody 
test (e.g. immunoblot). 
 
Confirmed cases: newly laboratory confirmed hepatitis C, 
regardless whether acute or chronic. 
Cases included in surveillance  Possible  
with classification 
Possible  
with classification 
 Probable Probable 
Confirmed  Confirmed  
Unknown classification  Unknown classification  
Type of cases Acute with classification Acute with classification 
 Chronic Chronic 
Asymptomatic Asymptomatic 
Suspected  Suspected  
Other:  Other:  
Including duplicates No Yes 
   
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other: Physicians and laboratory Other: Physicians and laboratory 
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
  
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other:  Other:  
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
Last population sero-survey in 1998, next one planned for 
2011. 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women   
Military recruits   
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**  HIV positives HIV positives 
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg + mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other: Travellers who travel to endemic areas; post-exposure prophylaxis 
Catch-up 
programme 
Individual catch-up vaccinations are administered during recommended doctors´ visits during childhood and adolescence. 
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: Children at school entry: 87% in 2006; 90.5% in 2008 
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Greece 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system Own system for HBV Own  system for HCV 
Comments   
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in 
disease distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical Clinical criteria: an acute illness with discrete onset of 
symptoms (e.g. jaundice); OR 
elevated serum aminotransferase levels. 
Laboratory criteria: IgM anti-HBc positive or HBV DNA 
positive. 
Confirmed: meets clinical criteria and laboratory confirmed 
Probable: meets clinical criteria AND positive HBsAg 
Clinical criteria: An acute illness with discrete onset of 
symptoms (e.g. jaundice) OR 
elevated serum aminotransferase levels; 
Laboratory criteria: anti-HCV positive and IgM anti-HAV 
negative AND anti-HB core IgM negative OR HCV RNA 
positive 
Confirmed: meets clinical criteria AND laboratory confirmed 
Probable: not applicable 
Chronic No case definition  No case definition 
Other HbsAg+, asymptomatic infants < 12 months: Other 
asymptomatic cases, antiHBc IgM+ or HbsAg+ 
Newly diagnosed HCV, asymptomatic (confirmed by anti-
HCV, first diagnosis). 
Cases included in surveillance  Possible  
 
Possible  
 
 Probable with classification Probable 
Confirmed Confirmed  
Unknown classification  Unknown classification  
Type of cases Acute with classification Acute with classification 
 Chronic  Chronic  
Asymptomatic  Asymptomatic  
Suspected  Suspected  
Other: HbsAg+, asymptomatic 
infants < 12 months: 
should be notified. 
Other asymptomatic cases 
(antiHBc IgM+ /  HbsAg+) 
should not be notified. 
Other: Newly diagnosed HCV, 
asymptomatic (confirmed 
by anti-HCV, first 
diagnosis) 
Including duplicates No No 
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
Clinical symptoms: jaundice and acute fulminant hepatitis 
are reported. 
Laboratory results: HbsAg, anti-HBc IgM, ALT, AST, other. 
High risk group 
Clinical symptoms: jaundice and acute fulminant hepatitis. 
Laboratory results: anti-HCV (EIA), anti-HCV (RIBA), HCV-
RNA,AST, ALT, other. 
Transmission risk factors: part of population at risk; 
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggre- 
gated 
Other: Case-based Aggre- 
gated 
Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other:  Other:  
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women    
Military recruits     
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**     
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg + mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other:  
Catch-up 
programme 
Childhood and adolescent population 
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage (3 doses of vaccination): Children 6 years: 95.3% in 2006; Adolescents 14 years: 84.7% in 2006 
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Hungary 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system HBV reporting is included in syndromic surveillance of viral 
hepatitis. 
HCV reporting is included in syndromic surveillance of viral 
hepatitis. 
Comments   
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
no no 
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical Possible (for acute viral hepatitis): n/a 
Probable: HBsAg-positive patient with clinical symptoms 
Confirmed: laboratory confirmation (hepB core IgM 
antibody positivity or HBV DNA in the blood) 
Possible: n/a 
Probable: n/a 
Confirmed: laboratory confirmation (HCV-specific antibody 
or HCV-RNA detection) plus clinical signs 
Chronic No case definition  No case definition 
Other   
Cases included in surveillance  Possible  Possible  
 
 Probable with classification 
 
Probable  
Confirmed  Confirmed with classification 
 
Unknown classification  Unknown classification  
Type of cases Acute with classification 
 
Acute with classification 
 
 Chronic Chronic 
Asymptomatic Asymptomatic 
Suspected  Suspected  
Other: Classification not needed; 
only acute cases included 
Other: Classification not needed; 
only acute cases included 
Including duplicates No No 
Underreporting  Underreporting is possible; please give the rate for 
underreporting (number of reported cases/estimated 
number of real cases) below. 
Underreporting is possible; please give the rate for 
underreporting (number of reported cases/estimated 
number of real cases) below. 
Rate underreporting 5% to 6% 5% to 6% 
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
Is infection sexually acquired? Is infection sexually acquired? 
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other:  Other:  
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
National organisation for blood and blood-borne products 
has its own register. 
National organisation for blood and blood-borne products 
has its own register. 
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Prevention 
  HBV 
 
HCV  
Screening 
programme 
Pregnant women   
Military recruits   
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**     
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg + mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other: Programme for school children 
Catch-up 
programme 
For 13-year-olds (in 2009) 
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: 95% to 98% in 2008% 
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Iceland 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system Own system for HBV Own  system for HCV 
Comments   
 
Objectives 
 HBV 
 
HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical All newly lab confirmed HBV cases are reportable, both 
acute and chronic cases, regardless of symptoms. 
EU case definitions 2008. 
Chronic Laboratory-confirmed cases with serological tests and 
medical history compatible with previous HBV infection. 
 EU case definitions 2008. 
Other Asymptomatic laboratory-confirmed cases are reportable.  
Cases included in surveillance  Possible  
 
Possible  
 
 Probable Probable 
Confirmed with classification 
 
Confirmed with classification 
 
Unknown classification  Unknown classification  
Type of cases Acute with classification 
 
Acute with classification 
 
 Chronic Chronic 
Asymptomatic Asymptomatic 
Suspected  Suspected  
Other:  Other:  
Including duplicates No No 
Underreporting  Underreporting not possible. Underreporting not possible. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
Classification: lab result: HBsAg, HBc antibodies, HBeAg, 
HBe antibodies 
Transmission risk factors: information on transmission 
route is always collected, even if it is not in the standard 
reporting form. 
Other: ICD: ICD-10 
Classification: lab result: HCV antibodies (ELISA), HCV 
antibodies (RIBA), HCV PCR 
Transmission risk factors: information on transmission 
route is always collected, even if it is not in the standard 
reporting form. 
Other: ICD: ICD-10 
Data linked to  Liver transplant Liver cancer   Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other:  Other:  
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
The National Treatment Centre of Addiction Medicine 
screens alcohol and drug addicts. 
The National Blood Bank screens blood donors. 
The National Treatment Centre of Addiction Medicine 
screens alcohol and drug addicts. 
The National Blood Bank screens blood donors. 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women    
Military recruits     
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**     
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg+ mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other:  
Catch-up 
programme 
  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: 
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Ireland 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system Own system for HBV Own  system for HCV 
Comments   
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other To facilitate resource allocation and health care planning. 
To guide public health action. 
To facilitate resource allocation and health care planning. 
To guide public health action. 
 
Case definition 
Definition  HBV  HCV 
Clinical Hepatitis B (acute and chronic): 
In symptomatic cases, clinical picture compatible with 
hepatitis, i.e. discrete onset of symptoms and/or jaundice 
or elevated serum aminotransferase levels. 
Asymptomatic cases are common (description in the EU 
case definition document has been elaborated upon); 
Hepatitis B (acute) (EU): 
Laboratory criteria for diagnosis. 
One of the following: 
• IgM antibody to hepatitis B core antigen (anti-HBc) 
positive 
• Detection of hepatitis B virus (HBV) nucleic acid in serum 
Case classification. 
Possible: n/a 
Probable: A symptomatic case that is HBsAg positive and 
has a clinical picture compatible with an acute hepatitis. 
Confirmed: A case that is laboratory confirmed. 
  
Clinical description. 
In symptomatic cases, clinical picture compatible with 
hepatitis, i.e. discrete onset of symptoms and/or jaundice 
or elevated serum aminotransferase levels. 
Asymptomatic cases are common (all laboratory-confirmed 
cases included; the EU definition is restricted to 
symptomatic cases) 
 Laboratory criteria for diagnosis. 
One of the following: 
• Detection of hepatitis C virus (HCV) specific antibodies 
• Detection of HCV nucleic acid from clinical samples 
Case classification. 
Possible: n/a 
Probable: n/a 
Confirmed: A case that is laboratory confirmed. 
 
 
Chronic Hepatitis B (chronic): 
Laboratory criteria for diagnosis. 
One of the following: 
• Hepatitis B surface antigen (HBsAg) positive and 
antibody to hepatitis B core antigen (anti-HBc) positive 
and IgM antibody to hepatitis B core antigen negative 
• Persistence for more than 6 months of either HBsAg or 
HBV nucleic acid in serum 
Case classification. 
Possible: n/a 
Probable: n/a 
Confirmed: A case that is laboratory confirmed. 
Note: Notification distinguishes between acute or chronic.  
  
Other   
Cases included in surveillance  Possible with classification Possible  
with classification  Probable  Probable 
Confirmed  Confirmed  
Unknown classification  Unknown classification  
Type of cases Acute 
with classification 
Acute 
with classification  Chronic Chronic 
Asymptomatic Asymptomatic 
Suspected  Suspected  
Other:  Other:  
Including duplicates No Yes 
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 HBV  HCV 
Underreporting  Underreporting is possible; please give the rate for 
underreporting (number of reported cases/estimated 
number of real cases) below. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting Estimated 25%  
 
Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
Lab results: HBsAg, HBeAg, anti-HBe, Anti-HBc, anti-HBc 
IgM, PCR/NA, genotype. 
Epi information: If linked to an outbreak. 
Other: Sex worker, intellectual disability setting. 
Lab details: HCV EIA, immunoblot, PCR, genotype. 
Epi information: if linked to an outbreak. 
Other: possible sexual exposure, most likely risk. 
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other: Quarterly Other: Quarterly 
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
 National database for those infected through blood and 
blood products (historical cohort) 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women    
Military recruits     
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**     
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg + mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other: Sexual partners and children of IDUs 
Patients receiving regular transfusions of blood or blood products 
Clients in centres for intellectual disability 
Prisoners 
Tattoo and body-piercing practitioners 
Families adopting children from high or intermediate HBV endemicity countries 
Short-term foster carers 
Immigrants from areas with a high or intermediate prevalence of HBV; Children 
born to parents from high or intermediate prevalence; Travellers to these 
countries 
Homeless people 
Catch-up 
programme 
  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: Infants: 89% in 2009 
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Italy 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system National National 
Comments The national surveillance system for acute viral hepatitis 
infection (SEIEVA, Sistema Epidemiologico Integrato 
dell’Epatite Virale Acuta), coordinated by the National 
Centre for Epidemiology, Surveillance and Health 
Promotion of the Istituto Superiore di Sanità, promotes the 
monitoring and control of acute viral hepatitis infection at 
both the local and national level. Epidemiological data are 
combined with laboratory data to estimate the impact of 
various risk factors, allowing prevention programmes to be 
defined and evaluated. 
Specific surveillance goals are:  
a) to determine the number of cases of acute viral hepatitis 
infection, by specific type of infection; b) to calculate the 
incidence of acute viral hepatitis infection, by type of 
infection, date and place of disease onset, age, and 
gender; c) to identify outbreaks in a timely manner; d) to 
calculate the proportion of cases exposed to specific risk 
factors, by type of infection; e) to study variations over 
time in the relative and attributable risks associated with 
specific types of exposure, by type of infection; f) to 
develop control strategies based on the identification of risk 
factors at the local level. (Continue on the right) 
 
The general methods of SEIEVA are:  
a) to interview infected persons using an individual 
questionnaire (SEIEVA form), which includes socio-
demographic and risk factor information; questionnaire is 
administered before results of serological tests are 
obtained;  
b) to provide information on the results of serological tests;  
c) to contact the transfusion centre and record information 
obtained on a specific form if the infected person reports 
that he/she had received a blood transfusion in the six 
months prior to disease onset;  
d) to conduct, when applicable (mainly when outbreaks are 
identified), case control and cohort studies.  
Participation is voluntary. The percentage of ASLs 
participating to the surveillance progressively increased 
from 5% in 1986 (about 3 million people) and in 2006 
represented 59% of total population (about 33.7 million 
people).  
Hepatitis C is currently reported as ‘non-A non-B hepatitis’, 
but the Italian surveillance system for infectious diseases is 
evolving and requires notification of specific hepatitis C. 
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical The diagnostic criteria used to identify acute viral hepatitis 
B is laboratory confirmation. 
Diagnostic criteria used to identify acute viral hepatitis C is 
laboratory confirmation. 
Chronic No case definition  No case definition 
Other   
Cases included in surveillance  Possible  Possible  
 Probable Probable 
Confirmed with classification Confirmed with classification 
Unknown classification  Unknown classification  
Type of cases Acute with classification Acute with classification 
 Chronic  Chronic  
Asymptomatic  Asymptomatic  
Suspected  Suspected  
Other:  Other:  
Including duplicates No No 
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
  
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other:  Other:  
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women    
Military recruits     
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**     
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents (12 years) 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg + mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other: Not specified 
Catch-up 
programme 
  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: 
Infants: 96% in 2008 
Comment: 12 year olds are included in universal vaccination programme since 1991 
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Latvia 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system HBV reporting is included in syndromic surveillance of viral 
hepatitis. 
HBV reporting is included in syndromic surveillance of viral 
hepatitis. 
Comments   
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical EU 2008 Case definition  
 
EU 2008 Case definition  
 
Chronic No case definition  No case definition 
Other   
Cases included in surveillance 
(highlighted in green) 
Possible  
 
Possible  
 
 Probable 
with classification 
Probable 
with classification 
Confirmed Confirmed 
Unknown classification  Unknown classification  
Type of cases Acute 
with classification 
Acute with classification 
 Chronic Chronic  
Asymptomatic Asymptomatic  
Suspected  Suspected  
Other:  Other:  
Including duplicates No No 
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other: Laboratories: detection of hepatitis C 
virus nucleic acid in serum 
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
Clinical symptoms: yellow skin or eyes. 
Laboratory results: HBV core IgM antibody, HbsAg. 
Transmisison risk factors: cosmetologist, police officer, 
soldier, blood donor, prisoner, laundress, person with 
chronic illness, person with mental illness. 
ICD-10 code: B16, B18.0, B18.1, Z22.5 
Clinical symptoms: yellow skin or eyes. 
Laboratory results: hepatitis C virus nucleic acid in serum, 
HCV IgM antibody. 
Transmission risk factors: cosmetologist, police officer, 
soldier, blood donor, prisoner, laundress, person with 
chronic illness, person with mental illness. 
ICD-10 code: B17.1, B18.2. 
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannual Yearly Monthly Biannually Yearly 
Other: Often if needed Other: Often if needed 
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women    
Military recruits     
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**    
  ‘Expanding Network for Comprehensive and Coordinated Action on HIV/AIDS 
Prevention Among IDUs and Bridging Population’, ENCAP No. 2005305;   
Anti-HBc prevalence among IDUs in Latvia in 2007: 55.8% 
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other: Universal vaccination: newborns (since 1998); adolescents (14-year-olds) (since 
2007). 
Risk group: healthcare and other workers who get in contact with blood (since 
2000). 
Catch-up 
programme 
Adolescents (14 years) in Riga in 2005-06  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage (2007): 
Infants (1-2 years of age): 97% 
Adolescents (15 years of age): 73.5% 
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Liechtenstein 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory  
Type of surveillance The laboratories report every positive HBV-test to the 
Office for Public Health, and the Office makes further 
inquiries. 
 
Surveillance system Own system for HBV  
Comments   
 
Objectives 
 HBV   
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
no  
Improve knowledge of 
epidemiology 
no  
Other no  
 
Case definition 
Definition  HBV   
Clinical No case definition  
Chronic No case definition   
Other   
Cases included in surveillance 
(highlighted in green) 
Possible  
with classification 
  
 Probable  
Confirmed    
Unknown classification    
Type of cases Acute with classification   
 Chronic  
Asymptomatic  
Suspected    
Other: Classification not needed, 
only acute cases included 
  
Including duplicates No  
Underreporting  Underreporting not possible.  
Rate underreporting   
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Data 
 HBV   
Source of data Physicians Laboratory Hospital    
 Other:    
Collected data Basic data Patient ID   
 Date of birth or age  
Gender  
Country of birth  
Place of residence  
Date of onset of the disease  
Date of diagnosis  
Date of reporting/notification  
Date used for statistics  
Country where infection was acquired  
Immunisation status  
Outcome  
 Classification 
information 
Clinical symptoms   
Laboratory results  
Epidemiological information  
Transmission 
route risk factors 
Homosexual contact   
Heterosexual contact  
Injecting drug use  
Mother HBsAg+  
Close family member HBsAg+  
Sex partner HBsAg+  
Blood or blood-product transfusion  
Invasive healthcare procedure/dental 
treatment 
 
Organ transplantation  
Haemodialysis  
Needle injury or other occupational 
exposure 
 
Tattooing/body piercing  
Other  
Other Hospitalisation   
Length of hospitalisation  
ICD code diagnosis  
Genotype information  
Jaundice only 
Lab: qualitative results (HbsAg, anti-HBc antibodies (IgM 
and total)) 
Quantitative results: ALAT 
 
Data linked to  Liver transplant Liver cancer Mortality    
 Hospital register      
Other:    
Format Electronic Paper   
Type Case-based Aggre- 
gated 
Other:    
   
Frequency Daily Weekly Biweekly    
 Monthly Biannually Yearly    
Other:    
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
   
Regular sero-surveys in general 
population 
Other   
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women   
Military recruits    
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**     
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other:  
Catch-up 
programme 
  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: 
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Lithuania 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system Own system for HBV Own  system for HCV 
Comments   
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical EU 2008 case definition EU 2008 case definition 
Chronic No case definition  No case definition 
Other   
Cases included in surveillance  Possible  
with classification 
Possible  
with classification  Probable Probable 
Confirmed  Confirmed  
Unknown classification  Unknown classification  
Type of cases Acute with classification Acute with classification 
 Chronic Chronic 
Asymptomatic Asymptomatic 
Suspected  Suspected  
Other: Comment: acute clinical, 
asymptomatic acute, and 
chronic cases are 
classified. Surveillance of 
chronic cases is not 
implemented. 
Other: Comment: acute clinical, 
asymptomatic acute, and 
chronic cases are 
classified. Surveillance of 
chronic cases is not 
implemented. 
Including duplicates No No 
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
Classification: HBsAg+, anti-HBc IgM+, HBV DNR, negative 
Transmission risk factors: commercial sex worker, prisoner, 
immigrant, asocial person, haemophilia patient, bisexual 
contact 
Other: ISD-10 
Classification: anti-HCV+, HCV RNR, negative 
Transmission risk factors: commercial sex worker, prisoner, 
immigrant, asocial person, haemophilia patient, bisexual 
contact 
Other: ISD-10 
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other:  Other:  
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women   
Military recruits   
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**     
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other:  
Catch-up 
programme 
  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: 
0-11-month-olds: 99.1%; 1-year-olds: 96.4% ; 13-year-olds: 97.2% 
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Luxembourg 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system HBV notified via mandatory notification system HCV notified via mandatory notification system 
Comments  . 
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other Monthly publication of statistics is required by law. Monthly publication of statistics is required by law. 
 
Case definition 
Definition  HBV  HCV 
Clinical No case definition No case definition 
Chronic No case definition  No case definition 
Other   
Cases included in surveillance Possible  
with classification 
Possible  
with classification 
 Probable Probable 
Confirmed  Confirmed  
Unknown classification  Unknown classification  
Type of cases Acute with classification Acute with classification 
 Chronic Chronic 
Asymptomatic Asymptomatic 
Suspected  Suspected  
Other:  Other:  
Including duplicates Yes Yes 
   
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
  
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other:  Other:  
Other surveillance systems STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women    
Military recruits     
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**     
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other:  
Catch-up 
programme 
  
Vaccination 
coverage 
Infants 0 to 2 years 
 Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: 
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Malta 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system Own system for HBV Own  system for HCV 
Comments   
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical Hepatitis B (acute); clinical description: 
In symptomatic cases, clinical picture compatible with 
hepatitis, e.g. discrete onset of symptoms and jaundice or 
elevated serum aminotransferase. 
Laboratory criteria for diagnosis: 
IgM antibody to hepatitis B core antigen (anti-HBc) 
positive; detection of HBV nucleic acid in serum 
Case classification: 
Possible: n/a 
Probable: HBsAg positive case with clinical picture 
compatible with acute hepatitis. 
Confirmed: Case, laboratory confirmed. 
Clinical description: 
In symptomatic cases, clinical picture compatible with 
hepatitis, e.g. discrete onset of symptoms and jaundice or 
elevated aminotransferase. 
Laboratory criteria for diagnosis: 
One of the following: 
Detection of hepatitis C virus (HCV)-specific antibodies; 
detection of HCV nucleic acid from clinical samples. 
Case Classification: 
Possible: n/a 
Probable: n/a 
Confirmed: symptomatic case, laboratory confirmed. 
Chronic No case definition  No case definition 
Other   
Cases included in surveillance  Possible  Possible  
 Probable 
with classification 
Probable 
with classification 
Confirmed Confirmed 
Unknown classification  Unknown classification  
Type of cases Acute with classification Acute with classification 
 Chronic Chronic 
Asymptomatic Asymptomatic 
Suspected  Suspected  
Other:  Other:  
Including duplicates No No 
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
  
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other:  Other:  
Other surveillance systems STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women   
Military recruits    
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**     
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other:  
Catch-up 
programme 
Catch-up campaign started in 2003, concurrently with introduction of universal hepatitis B vaccination for children aged 15 months. This 
will be completed in 2008-09 
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: 
Infants aged 15 months in 2007: First dose: 74.68%; Second dose: 74.14%; Third dose: 76.22% Doctors in private practice do not 
report vaccinations, so we do not know how many were vaccinated privately. 
In 2007, we continued with catch up for 7-8 year-olds in schools :  First dose: 90.2%; Second dose: 85.7%; Third dose: 82.3%. 
We do not vaccinate 10-14-year-olds as they are already vaccinated. 
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Netherlands 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system Own system for HBV Own  system for HCV 
Comments   
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical Any person with a discrete onset of symptoms (e.g. 
fatigue, abdominal pain, loss of appetite, intermittent 
nausea and vomiting) 
AND 
at least one of the following two: 
jaundice; elevated serum aminotransferase levels 
AND 
hepatitis B virus core IgM or HBsAg positive 
Every new diagnosis of HCV infection must be notified 
when suspecting a recent infection (last year). Suspicion of 
a recent infections can originate from: 
• appearance of antibodies against HCV, or increase in 
laboratory reactivity; 
• symptoms (e.g. icterus or increased liver function 
disorder); 
• exposure to relevant risks if present in recent period, 
including medical treatments. 
Chronic HBsAg positive  No case definition 
Other   
Cases included in surveillance  Possible  
 
Possible  
 
 Probable Probable 
Confirmed with classification Confirmed with classification 
Unknown classification  Unknown classification  
Type of cases Acute  
with classification 
Acute with classification 
 Chronic  Chronic 
Asymptomatic  Asymptomatic 
Suspected  Suspected  
Other:  Other:  
Including duplicates No No 
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other: Municipal health services Other: Municipal health services 
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
  
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other:  Other:  
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women    
Military recruits     
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**     
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other: Persons with Down’s syndrome 
All newborns with at least one parent originating from an HBV-endemic country 
Drug users, commercial sex workers, men who have sex with men 
Catch-up 
programme 
  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage Infants born to one or two parents from an endemic country: 96% in 2008 (three HBV vaccinations or more) 
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Norway 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system Own system for HBV Own  system for HCV 
Comments   
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical No case definition No case definition 
Chronic Detection of HBsAg and anti-HBc for more than 6 months 
and with no clinical picture of acute hepatitis. 
 No case definition 
Other Any person with clinical acute hepatitis and presence of 
HbsAg and one of the following laboratory criteria: HbeAg, 
HBV-RNA, anti-Hbc (IgG or IgM); or any person with 
confirmed anti-Hbc seroconversion in the last 12 months 
and one of the following laboratory criteria: HbsAg, HBV-
RNA, anti-HbsAb (with no history of previous vaccination). 
Common case definition for both acute and chronic HCV: 
Any person meeting with one of the following  laboratory 
criteria: anti-HCV, HCV-RNA. 
Cases included in surveillance  Possible  
 
Possible  
with classification 
 Probable  Probable 
Confirmed with classification Confirmed  
Unknown classification  Unknown classification  
Type of cases Acute  
with classification 
Acute with classification 
 Chronic  Chronic 
Asymptomatic  Asymptomatic 
Suspected  Suspected  
Other:  Other:  
Including duplicates No Yes 
   
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
  
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other:  Other:  
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women   
Military recruits     
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**     
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg + mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other: Risk group vaccination: Men who have sex with men 
Risk group vaccination: Neonates born to immigrants from countries with 
medium or high prevalence, and all immigrants from countries with medium or 
high prevalence. 
Risk group vaccination: commercial sex workers 
Catch-up 
programme 
  
Vaccination 
coverage 
Infants 0 to 2 years 
 Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: 
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Poland 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system Own system for HBV Own  system for HCV 
Comments   
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical EU 2008 case definition EU 2008 case definition 
 
Chronic No case definition  Newly detected hepatitis C cases: 
probable antibodies detected by screening type assay and 
not excluded by immunoblot. 
Confirmed antibodies confirmed by immunoblot (RIBA or 
other) or detection of viral genetic material in clinical 
samples. 
Other  Comment: Temporarily collected data are simultaneously 
classified according to EU 2002 and 2008 case definitions, 
in order to better monitor trends. 
Cases included in surveillance  Possible  
 
with classification 
Possible  
 
 Probable Probable with classification 
Confirmed  Confirmed  
Unknown classification  Unknown classification  
Type of cases Acute with classification Acute with classification 
 Chronic Chronic 
Asymptomatic  Asymptomatic 
Suspected  Suspected  
Other:  Other: Classification comments: 
symptomatic cases 
(including elevated liver 
function tests) can be 
differentiated from 
asymptomatic cases 
Including duplicates Unlikely, but possible duplicate removal at the regional 
level. 
Unlikely, but possible duplicate removal at the regional 
level. 
   
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
  
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other: Aggregated data are provided bi-weekly 
for hepatitis B (number of cases, acute 
and chronic) and yearly, with some 
demographic break-up. Individual level 
data, paper based, for acute hepatitis B 
are forwarded quarterly. 
Other: Aggregated data are provided bi-
weekly for hepatitis C (numbers 
according to 2002 and 2008 EU case 
definitions) and yearly, with some 
demographic break-up. Individual level 
data, paper based, for hepatitis C 
(according to 2002 EU case definition) 
are forwarded quarterly. 
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
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Prevention 
  HBV 
 
 
Screening 
programme 
Pregnant women   
Military recruits   
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners  Only if tattooed or injecting drug user 
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**    
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg + mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other: HIV-infected persons; residents of long-term stationary facilities, childcare 
centres; persons scheduled for surgery for cardiopulmonary bypass 
Catch-up 
programme 
  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage (two or three doses): 
Year of birth: coverage in percent 
2008: 90.2 
2007: 99.8 
2006: 99.9 
2005: 99.9 
2004: 100 
2003: 100 
2002: 100 
2001: 100 
2000: 100 
1999: 100 
1998: 100 
1997: 100 
1996: 99.1 
1995: 92.4 
1994: 98.7 
1993: 99.1 
1992: 99.3 
1991: 99.5 
1990: 99.5 
1989: 99.6 
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Portugal 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
yes  yes 
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system Included in the national mandatory surveillance system for 
communicable diseases. 
Included in the national mandatory surveillance system for 
communicable diseases. 
Comments   
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical Acute disease, with insidious onset of symptoms (fever, 
malaise, anorexia, nausea, vomiting) and elevation of 
serum transaminase levels, with or without icterus. 
Acute disease with insidious clinical symptoms (fever, 
malaise, anorexia, nausea, astenia) and elevation of serum 
transaminase levels, with or without icterus. 
Chronic 
No case definition 
 
No case definition 
Other Probable case: person with disease compatible with the 
case definition for clinical HBV, epidemiologically related to 
a laboratory-confirmed case (cohabitant/sexual partner) 30 
to 180 days before onset of symptoms. 
Confirmed case: case compatible with case definition for 
clinical HBV and confirmed by lab (IgM anti HBc in serum). 
Probable case: case compatible with the clinical description 
and epidemiologically linked to another case with 
laboratory confirmation (during the incubation period). 
Confirmed case: case compatible with the clinical 
description and laboratory confirmed. 
Cases included in surveillance  Possible  
with classification 
Possible  
 Probable Probable with classification 
Confirmed  Confirmed  
Unknown classification  Unknown classification  
Type of cases Acute  
with classification 
Acute  
with classification 
 Chronic Chronic 
Asymptomatic Asymptomatic 
Suspected  Suspected  
Other: Classification not 
necessary; only acute 
cases included. 
Other: Classification not 
necessary; only acute 
cases included. 
Including duplicates No No 
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
The form is used for all communicable diseases in the 
system, so data about clinical symptoms, laboratory 
results, and epidemiological information may be given as  
free-text responses, or in a Yes/No format. 
Laboratory results not specified, only Yes/No; four 
variables with epidemiological information; ICD-10 
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other:  Other: Quarterly 
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women    
Military recruits    
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**     
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other:  
Catch-up 
programme 
  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: 
97% fully vaccinated children at 12 months of age; 
92% vaccination coverage at 14 years of age. 
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Romania 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system HBV reporting is included in syndromic surveillance of viral 
hepatitis. 
HCV reporting is included in syndromic surveillance of viral 
hepatitis. 
Comments   
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks no no 
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other To monitor the impact of the universal vaccination 
programme. 
no 
 
Case definition 
Definition  HBV  HCV 
Clinical Clinical criteria: acute disease with discrete onset and 
jaundice or increased aminotransferase levels. 
Lab criteria for confirmed cases: presence of specific 
antigens to the core antigen (AntiHBc-IgM); detection of 
the nucleic acid in serum. 
Acute disease with discrete onset 
AND 
hepatitis C virus-specific antibody response 
OR 
detection of hepatitis C virus nucleic acid in serum. 
Chronic 
No case definition 
 
No case definition 
Other   
Cases included in surveillance  Possible with classification Possible with classification 
 Probable Probable 
Confirmed  Confirmed  
Unknown classification  Unknown classification  
Type of cases Acute with classification Acute with classification 
 Chronic Chronic 
Asymptomatic Asymptomatic 
Suspected  Suspected  
Other: Classification not 
necessary; only acute 
cases included. 
Other: Based on anti-HCV 
antibodies; we cannot 
differentiate. 
Including duplicates No Yes 
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
  
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other:  Other:  
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women     
Military recruits     
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**     
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg + mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other:  
Catch-up 
programme 
  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: Infants: 98%; Adolescents: 97% 
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Slovakia 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Epidemiologists investigate each reported suspect case or 
each laboratory-positive result directly with patients and 
their contacts. 
Any suspect case of viral hepatitis is investigated by 
epidemiologists. 
Surveillance system Own system for HBV Own  system for HCV 
Comments   
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other To evaluate existing preventive measures. no 
 
Case definition 
Definition  HBV  HCV 
Clinical Any person with a discrete onset of symptoms (e.g. 
fatigue, abdominal pain, loss of appetite, intermittent 
nausea and vomiting) 
AND  
at least one of the following: fever; jaundice; elevated 
serum aminotransferase levels, confirmed lab test 
Symptomatic case which is laboratory confirmed. 
Chronic    
Other   
Cases included in surveillance  Possible  
 
Possible  
with classification 
 Probable 
with classification 
Probable 
Confirmed Confirmed  
Unknown classification  Unknown classification  
Type of cases Acute  
with classification 
Acute with classification 
 Chronic Chronic 
Asymptomatic Asymptomatic 
Suspected  Suspected  
Other:  Other:  
Including duplicates No No 
Underreporting  Underreporting not possible. Underreporting not possible. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
ICD- 10 codes for acute, chronic, and asymptomatic cases. 
B16: acute HBV 
B18.1: chronic HBV 
Z22.5: carrier of HBsAg 
ICD-10 
B17.1: acute HVC 
B18.2: chronic HVC 
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other: Determined by need Other: Determined by need. 
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
  
 
  
 
 
 
 
TECHNICAL REPORT Surveillance and prevention of hepatitis B and C in Europe 
 
 
 
123 
 
 
 
Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women    
Military recruits   
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**     
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg + mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other: Risk group vaccination: patients with other type of viral hepatitis  (hepatitis A, 
hepatitis C) 
Catch-up 
programme 
  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage:  
0-2 years: 98.5% 
10-14 years: 98% 
Health professionals: 88% 
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Slovenia 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system Own system for HBV Own  system for HCV 
Comments   
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical EU 2008 case definition 
Current definition: A case that is HBsAg + with a clinical 
picture compatible with acute hepatitis; 
any person with a discrete onset of symptoms (fatigue, 
abdominal pain, loss of appetite, intermittent nausea and 
vomiting) 
EU 2008 case definition 
Clinical picture compatible with hepatitis;. 
Chronic No case definition 
 
EU 2008 case definition 
Other   
Cases included in surveillance  Possible  
With classification 
Possible With classification 
 
 Probable Probable 
Confirmed  Confirmed  
Unknown classification  Unknown classification  
Type of cases Acute 
With classification 
Acute 
With classification  Chronic Chronic 
Asymptomatic Asymptomatic 
Suspected  Suspected  
Other: Almost all reported cases 
are laboratory confirmed. 
Cases on notification 
forms are classified as 
acute and chronic ones; 
asymptomatic cases can 
be classified according to 
data from questionnaires. 
Notification system will 
change in the future. 
Other: Acute and chronic forms 
can be differentiated from 
notification forms, other 
data are gathered from 
questionnaires. 
Including duplicates No No 
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
Above information is available from notification form; other 
information (including laboratory results) are available if 
questionnaires are filled in. 
Above information is available from notification form; other 
information (including laboratory results) are available if 
questionnaires are filled in. 
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other: Automatic linking is not possible. 
Individual cases can be found in 
other registers through personal 
data. 
Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other: In case of clusters or outbreaks we 
analyse data more frequently. 
Other: In case of outbreaks, data are 
analysed more frequently. 
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women    
Military recruits     
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**    
  Screening of prisoners. Most screenings are conducted for risk groups. The 
Slovenian armed forces are vaccinated ofr HBV according to risk assessments 
connected to working places and standards of peacekeeping missions. 
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg + mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups 
Other: Universal vaccination programme for children before they enter primary school. 
Catch-up 
programme 
Vaccination catch-up was offered for young people  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: Among compulsory vaccinated children aged 7 years: 97.3% in 2007 
 
 
  
 
 
 
 
TECHNICAL REPORT Surveillance and prevention of hepatitis B and C in Europe 
 
 
 
127 
 
 
 
Spain 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system Several surveillance systems for HBV, one of which is the 
major and most comprehensive one. 
Several surveillance systems for HCV, one of which is the 
major and most comprehensive one. 
Comments  HCV is included in the syndromic surveillance of viral 
hepatitis. In addition, data on HCV are collected through a 
voluntary reporting system based on reports sent by the 
microbiology laboratories in hospitals  
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
 no 
Evaluation and planning of 
control measures 
 no 
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical Any person with a discrete onset of symptoms (e.g. 
fatigue, abdominal pain, loss of appetite, intermittent 
nausea and vomiting) 
AND 
at least one of the following three: fever; jaundice; 
elevated serum aminotransferase levels. 
An acute illness with a discrete onset of any sign or 
symptom consistent with acute viral hepatitis (e.g. 
anorexia, abdominal discomfort, nausea, vomiting and 
jaundice) and increase in transaminase (ALT, AST). 
Chronic No case definitions  No case definitions 
Other   
Cases included in surveillance  Possible  
 
Possible  
 
 Probable 
with classification 
Probable 
with classification 
Confirmed Confirmed 
Unknown classification  Unknown classification  
Type of cases Acute with classification Acute with classification 
 Chronic Chronic 
Asymptomatic Asymptomatic 
Suspected  Suspected  
Other:  Other:  
Including duplicates Yes Yes 
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
  
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other:  Other:  
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women   
Military recruits     
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**     
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg + mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other:  
Catch-up 
programme 
  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: Infants: 98% (2004) Adolescents: 78% (2004) 
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Sweden 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Mandatory Mandatory 
Type of surveillance Passive Passive 
Surveillance system Own system for HBV Own  system for HCV 
Comments SmiNet SmiNet 
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical No case definition No case definition 
Chronic HBV chronic infection: HBsAg positive 
AND 
anti-HBc IgG positive 
AND 
not detectable or low levels of anti-HBc IgM 
 HCV RNA positive and HCV antibody positive 
Other HBV acute infection:  
HBsAg + OR HBV-DNA + 
AND 
anti-HBcIgM + OR HBV-DNA + with or without detectable 
HBsAg AND not detectable anti-HBc. 
HCV acute infection: seroconversion to anti-HCV within 6 
months between the samples. 
Cases included in surveillance  Possible  
 
Possible  
with classification 
 Probable 
with classification 
Probable 
Confirmed Confirmed  
Unknown classification  Unknown classification  
Type of cases Acute  
with classification 
Acute  
with classification 
 Chronic  Chronic  
Asymptomatic  Asymptomatic  
Suspected  Suspected  
Other:  Other:  
Including duplicates No No 
Underreporting  Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Underreporting is possible, but no estimates exist for 
magnitude of underreporting. 
Rate underreporting   
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
  
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other: It is not possible to link HBV cases 
to other registers except to 
mortality in the ordinary 
surveillance system. Linking can be 
done in special studies. 
Other: Except for mortality, HCV cases 
cannot be linked to other registers 
from the ordinary surveillance 
system. Linking can be done in 
special studies 
Format Electronic Paper Electronic Paper 
Type Case-based Aggre- 
gated 
Other: Case-based Aggre- 
gated 
Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other:  Other:  
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women    
Military recruits     
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**     
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg + mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups: individuals at risk for HBV due to occupation 
Other:  
Catch-up 
programme 
  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: 
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United Kingdom 
 HBV  HCV 
Surveillance system  
Included in the national 
surveillance system 
   
Legal basis (mandatory/ 
voluntary) 
Voluntary Voluntary 
Type of surveillance It includes information from multiple sources, primarily the 
laboratory carrying out the testing to detect changing 
patterns in hepatitis B. Blood specimens are tested to 
determine acute hepatitis B infection. 
It includes information from multiple sources, including the 
microbiology laboratory to detect changing patterns of 
hepatitis C infection. Blood specimens are tested  to 
determine hepatitis C exposure. 
Surveillance system Several surveillance systems for HBV, one of which is the 
major and most comprehensive one. 
Several surveillance systems for HCV, one of which is the 
major and most comprehensive one. 
Comments   
 
Objectives 
 HBV  HCV 
Monitoring trends   
Detect outbreaks   
Monitoring changes in disease 
distribution 
  
Evaluation and planning of 
control measures 
  
Improve knowledge of 
epidemiology 
  
Other no no 
 
Case definition 
Definition  HBV  HCV 
Clinical HBsAg + and anti-HBc IgM + and abnormal liver function 
tests with a pattern consistent with acute viral hepatitis. 
Case definition for surveillance: 
Recent seroconversion 
OR 
hepatitis C RNA or antigen + and anti-HCV - or equivocal in 
otherwise immunocompetent individual 
OR 
anti-HCV +, anti-HAV IgM -, and anti-HBc IgM - and 
abnormal liver function tests with a pattern consistent with 
acute viral hepatitis in someone with recent exposure to 
HCV e.g. needlestick injury, dialysis, recent injecting drug 
use. 
Chronic Chronic HBV case definition: 
HBsAg + twice at least 6 months apart 
OR 
HBsAg + and anti-HBc IgM2,- and anti-HBc + 
 Case definition for surveillance: 
Anti-HCV positive 
OR 
HCV RNA+ and not meeting case definition for acute HCV. 
Other   
Cases included in surveillance  Possible  
with classification 
Possible  
with classification  Probable Probable 
Confirmed  Confirmed  
Unknown classification  Unknown classification  
Type of cases Acute 
 
with classification 
Acute 
with classification  Chronic Chronic 
Asymptomatic Asymptomatic 
Suspected  Suspected  
Other:  Other:  
Including duplicates Yes Yes 
Underreporting  Underreporting is possible; please give the rate for 
underreporting (number of reported cases/estimated 
number of real cases) below. 
Underreporting is possible; please give the rate for 
underreporting (number of reported cases/estimated 
number of real cases) below. 
Rate underreporting The proportion of underreporting is assumed to be 25%. 
Ramsay M, et al. Control of hepatitis B in the UK. Vaccine 
1998;16(Suppl):S52–5. 
Data suggest that routine laboratory reporting may 
underestimate the numbers of diagnosed hepatitis C 
infections by up to 60% (HPA Annual Report 2007). 
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Data 
 HBV  HCV 
Source of data Physicians Laboratory Hospital Physicians Laboratory Hospital 
 Other:  Other:  
Collected data Basic data Patient ID Basic data Patient ID 
 Date of birth or age Date of birth or age 
Gender Gender 
Country of birth Country of birth 
Place of residence Place of residence 
Date of onset of the disease Date of onset of the disease 
Date of diagnosis Date of diagnosis 
Date of reporting/notification Date of reporting/notification 
Date used for statistics Date used for statistics 
Country where infection was acquired Country where infection was acquired 
Immunisation status Immunisation status 
Outcome Outcome 
 Classification 
information 
Clinical symptoms Classification 
information 
Clinical symptoms 
Laboratory results Laboratory results 
Epidemiological information Epidemiological information 
Transmission 
route risk factors 
Homosexual contact Transmission 
route risk factors 
Homosexual contact 
Heterosexual contact Heterosexual contact 
Injecting drug use Injecting drug use 
Mother HBsAg+ Mother HCV positive 
Close family member HBsAg+ Close family member HCV- positive 
Sex partner HBsAg+ Sex partner HCV positive 
Blood or blood-product transfusion Blood or blood-product transfusion 
Invasive healthcare procedure/dental 
treatment 
Invasive healthcare procedure/dental 
treatment 
Organ transplantation Organ transplantation 
Haemodialysis Haemodialysis 
Needle injury or other occupational 
exposure 
Needle injury or other occupational 
exposure 
Tattooing/body piercing Tattooing/body piercing 
Other Other 
Other Hospitalisation Other Hospitalisation 
Length of hospitalisation Length of hospitalisation 
ICD code diagnosis ICD code diagnosis 
Genotype information Genotype information 
  
Data linked to  Liver transplant Liver cancer Mortality Liver transplant Liver cancer Mortality 
 Hospital register   Hospital register   
Other:  Other:  
Format Electronic Paper Electronic Paper 
Type Case-based Aggregated Other: Case-based Aggregated Other: 
   
Frequency Daily Weekly Biweekly Daily Weekly Biweekly 
 Monthly Biannually Yearly Monthly Biannually Yearly 
Other: Quarterly Other: Quarterly 
Other surveillance 
systems 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
STI clinic 
surveillance 
Laboratory 
network 
Supplementary 
sentinel surveillance 
Regular sero-surveys in general 
population 
Other Regular sero-surveys in general 
population 
Other 
Annual surveys of the prevalence of anti-HBc in oral fluid 
specimens from injecting drug users. 
A sentinel laboratory surveillance system monitors HCV 
testing. The annual survey of anti-HCV testing in injecting 
drug users (oral fluid specimens are tested for anti-HCV) 
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Prevention 
  HBV 
 
HCV 
Screening 
programme 
Pregnant women   
Military recruits   
Injecting drug users   
STI clinic patients   
Multiple sex partners   
Prisoners   
Haemodialysis patients   
Long-term healthcare facilities   
Healthcare workers   
Workers who are occupationally exposed to the virus   
Blood and organ donors   
Other groups**     
Vaccination 
programme 
HBV  
(only HBV) Universal vaccination Infants 
 Adolescents 
Both 
Other 
Risk groups vaccination Neonates born to HBsAg mothers 
Individuals at risk for HBV due to occupation 
Haemodialysis patients 
Chronic liver disease patients 
STI clinic patients 
Multiple sex partners 
Injecting drug users 
Household contacts of HBsAg+ patients 
Contacts of infected persons 
Other risk groups** 
Other: Staff of residential and other accommodation for those with learning difficulties; 
people travelling to and going to reside in high prevalence areas 
Catch-up 
programme 
  
Vaccination 
coverage 
Infants 0 to 2 years 
Adolescents 10 to 14 years 
Adults 
Other groups 
Not known 
Coverage: 
Homosexual men who attend genitourinary medicine clinics (HepB3 study; 44% in 2005 and 38% in 2006).  
 
For prisons: 37.5% in 2007; 47.5% in 2008 
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